WO1999050247A1 - Compounds with activity on muscarinic receptors - Google Patents

Compounds with activity on muscarinic receptors Download PDF

Info

Publication number
WO1999050247A1
WO1999050247A1 PCT/US1999/007057 US9907057W WO9950247A1 WO 1999050247 A1 WO1999050247 A1 WO 1999050247A1 US 9907057 W US9907057 W US 9907057W WO 9950247 A1 WO9950247 A1 WO 9950247A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
compound
alkoxy
composition
halo
Prior art date
Application number
PCT/US1999/007057
Other languages
French (fr)
Inventor
Mark Robert Brann
Terri Messier
Erika Anne Currier
Katharan Lauri Duggento
Mikael Friberg
Niels Skjaerbaek
Tracy Spalding
Original Assignee
Acadia Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharmaceuticals, Inc. filed Critical Acadia Pharmaceuticals, Inc.
Priority to NZ507204A priority Critical patent/NZ507204A/en
Priority to MXPA00009569A priority patent/MXPA00009569A/en
Priority to AU32187/99A priority patent/AU762726B2/en
Priority to BR9909277-8A priority patent/BR9909277A/en
Priority to EP99914306A priority patent/EP1068185A1/en
Priority to JP2000541152A priority patent/JP2002509918A/en
Priority to CA002326804A priority patent/CA2326804C/en
Publication of WO1999050247A1 publication Critical patent/WO1999050247A1/en
Priority to NO20004912A priority patent/NO319835B1/en
Priority to US11/933,177 priority patent/US20080108618A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • the present invention relates to novel compounds which are selective for muscarinic acetylcholine receptor subtypes, as well as to methods for activating muscarinic receptors and for treating or alleviating diseases in which modification of muscarinic receptor activity is beneficial.
  • Muscarinic acetylcholine receptors play a central role in the central nervous system for higher cognitive functions, as well as in the peripheral parasympathetic nervous system. Cloning has established the presence of five distinct muscarinic receptor subtypes (termed ml-m5) (cf. T.I. Bonner et al, Science 237, 1987, pp. 527- 532; T.I. Bonner et al., Neuron 1, 1988, pp. 403-410).
  • ml is the predominant subtype in the cerebral cortex and is believed to be involved in the control of cognitive functions
  • m2 is predominant in heart and is believed to be involved in the control of heart rate
  • m3 is believed to be involved in gastrointestinal and urinary tract stimulation as well as sweating and salivation
  • m4 is present in brain
  • m5 is present in brain and may be involved certain functions of the central nervous system associated with the dopaminergic system.
  • muscarinic ligands Animal studies of various muscarinic ligands (S. Iversen, Life Sciences 60 (Nos. 13/14), 1997, pp. 1 145-1152) have shown that muscarinic compounds have a profound effect on cognitive functions, e.g. learning and memory. This would suggest a potential utility of muscarinic agonists in the improvement of cognitive functions in diseases characterized by cognitive impairment, both age-related (such as Alzheimer ' s disease or other dementias) and not age-related (such as attention deficit hyperactivity disorder).
  • age-related such as Alzheimer ' s disease or other dementias
  • attention deficit hyperactivity disorder such as attention deficit hyperactivity disorder
  • muscarinic receptor subtype is the more abundant one in the cerebral cortex, basal ganglia and hippocampus where it accounts for 35-60% of all muscarinic receptor binding sites (cf. A. Levey, Proc. Natl. Acad. Sci.. USA 93, 1996, pp. 13541- 13546).
  • the ml (and possibly m4) subtype plays a major role as a postsynaptic muscarinic receptor (located on cholinoceptive neurons in the neocortex and hippocampus) in various cognitive and motor functions and is likely to be a major contributor to the ml responses measured in these regions of the brain.
  • conditions associated with cognitive impairment such as Alzheimer's disease, are accompanied by selective loss of acetylcholine in the brain. This is believed to be the result of degeneration of cholinergic neurons in the basal forebrain which innervate areas of the association cortex and hippocampus involved in higher processes (cf. S. Iversen, supra). This finding would suggest that such conditions may be treated or at least ameliorated with drugs that augment the cholinergic function in the affected areas of the brain.
  • acetylcholine esterase (AChE) inhibitors such as 9-amino-l,2,3,4- tetrahydroacridine (tacrine) results in an increase of acetylcholine in the brain which indirectly causes stimulation of muscarinic receptors.
  • AhE acetylcholine esterase
  • tacrine 9-amino-l,2,3,4- tetrahydroacridine
  • Tacrine treatment has resulted in a moderate and temporary cognitive improvement in Alzheimer's patients (cf. Kasa et al., supra).
  • tacrine has been found to have cholinergic side effects due to the peripheral acetylcholine stimulation. These include abdominal cramps, nausea, vomiting, diarrhea, anorexia, weight loss, myopathy and depression. Gastrointestinal side effects have been observed in about a third of the patients treated.
  • Tacrine has also been found to cause significant hepatotoxicity, elevated liver transaminases having been observed in about 30% of the patients (cf. P. Taylor, "Anticholinergic Agents". Chapter 8 in Goodman and Gilman: The Pharmacological Basis of Therapeutics, 9 th Ed., 1996, pp. 161-176).
  • the adverse effects of tacrine have severely limited its clinical utility.
  • Another AChE inhibitor, (R,S)-l-benzyl-4-[5,6- dimethoxy-l-indanon-2yl]methylpiperidine.HCl (donepezil) has recently been approved for the treatment of symptoms of mild to moderate Alzheimer ' s disease (cf. P. Kasa et al, supra). No hepatic damage has been observed for this compound but it has gastrointestinal effects similar to those of tacrine, probably due to stimulation of the m3 receptor caused by elevated parasympathetic tone.
  • muscarinic agonists (believed to be ml selective) hitherto suggested for the treatment of Alzheimer's disease, such as arecoline, have not shown greater efficacy in clinical trials than AChE inhibitors (cf. S.V.P. Jones et al., supra).
  • arecoline was found to have not so much cognitive enhancing effects as effects on behavioral changes often observed in Alzheimer's disease patients, such as a significant increase in motor activity, significant uplifting of mood, and significant decrease in anergia.
  • ml agonists have later been found to be weak partial agonists selective for the m2 and/or m3 receptor subtypes (H. Brauner-Osborne et al., J. Med. Chem. 38, 1995, pp. 2188-2195).
  • m2 subtype selectivity is presumed to be responsible for the cardiovascular effects observed for these agonists, e.g. tachycardia and bradycardia, and m3 activity is believed to account for the adverse gastrointestinal effects of the agonists.
  • m2 and/or m3 activity is therefore a significant drawback for the muscarinic agonists proposed until now for the treatment of Alzheimer's disease, severely limiting the doses of the drugs which it has been possible to administer to patients who may therefore have received sub-optimal doses.
  • the lack of subtype selectivity and low potency of the currently tested cholinergic compounds appear to favor the negative peripheral side effects and have limited cognitive effects because of weak and/or opposing actions in the brain. It would therefore be of great advantage to develop compounds which have an improved selectivity for the ml subtype, but which have little or no activity on the m2 and m3 subtypes.
  • the present invention provides compounds with muscarinic agonist activity of the general formula (I):
  • Xi, X 2 , X 3 , X4 and X5 are selected from C, N and O; k is 0 or 1; t is 0, 1 or 2;
  • Ri is straight or branched-chain d-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C ⁇ -8 alkylidene, C ⁇ - alkoxy, C ⁇ -8 heteroalkyl, C ⁇ -8 aminoalkyl, C ⁇ -8 haloalkyl, C ⁇ -8 alkoxycarbonyl, C ⁇ -8 hydroxyalkoxy, C ⁇ -8 hydroxyalkyl, -SH, C ⁇ -8 alkylthio, -O-CH 2 -
  • -C(O)-C 5-6 aryl substituted with C ⁇ -3 alkyl or halo; C 5-6 aryl or C 5-6 cycloalkyl optionally comprising 1 or more heteroatoms selected from N, S and O; -C(O)NR 3 R 4 ,
  • R 4 and R are the same or different, each independently being selected from H, C ⁇ -6 alkyl; C 5 - 6 aryl optionally comprising 1 or more heteroatoms selected from N, O and
  • A is C 5- ⁇ 2 aryl or C 5- cycloalkyl, each optionally comprising 1 or more heteroatoms selected from N, S and O;
  • R 2 is H, amino, hydroxyl, halo, or straight or branched-chain C ⁇ -6 alkyl, C -6 alkenyl, C 2-6 alkynyl, C ⁇ - alkoxy, C ⁇ - heteroalkyl, C ⁇ - 6 aminoalkyl, C ⁇ - haloalkyl, C1.6 alkylthio, C ⁇ -6 alkoxycarbonyl, -CN, -CF 3 , -OR 3 , -COR 3 , NO 2 , -NHR 3 , - NHC(O)R 3 , -C(O)NR 3 R 4 , -NR3R1, -NR3C(O)NR4R 5 , -OC(O)R 3 , -C(O)R 3 R4, -O(CH 2 ) q NR 3 , -CNR 3 t or -(CH 2 ) q NR 3 R4; where q is an integer from 1 to 6; n is 0, 1, 2, 3
  • Z is CR 8 R 9 wherein R 8 and R are independently selected from H, and straight or branched chain C ⁇ . 8 alkyl; or a pharmaceutically acceptable salt, ester or prodrug thereof.
  • the present invention further provides pharmaceutical compositions comprising an effective amount of a compound of formula (I).
  • compositions comprising a compound of formula (I).
  • the present invention provides a method of treating the symptoms of a disease or condition associated with increased intraocular pressure. such as, for example, glaucoma, where the method comprises administering a therapeutically effective amount of a composition comprising a compound of formula
  • Figure 1 is a graph showing raw data from one 96-well microtiter plate of screening of 35,000 small organic molecules in the assay described in Example XVI.
  • Figure 2 is a graph showing data comparing the profile of the reference antagonist atropine with ml muscarinic receptor transfected cells stimulated with either carbachol (open triangles) or compound A (Example I) (closed triangles).
  • the present invention provides compounds preferably showing a relatively high selectivity towards the ml receptor subtype relative to other muscarinic subtypes which may have a beneficial effect in the treatment of cognitive impairment such as Alzheimer's disease or other conditions associated with age-related cognitive decline while avoiding the adverse affects of the drugs hitherto suggested for this purpose.
  • Compounds exhibiting this property have surprisingly been isolated by screening against ml-m5 receptor subtypes.
  • the present invention provides compounds of formula (I), wherein
  • - 5 - Xi, X 2 , X 3 , X4 and X 5 are C; or one of Xi, X 2 , X 3 , X 4 or X 5 is O or N and the others are C; k is 0 or 1 ; t is 1; Ri is straight or branched-chain C ⁇ -8 alkyl, C 2-8 alkenyl, C -8 alkynyl, C ⁇ -8 alkylidene, C ⁇ -8 alkoxy, C ⁇ -8 aminoalkyl, C ⁇ -8 haloalkyl, C ⁇ -8 alkoxycarbonyl, -C(O)NR 3 R 4 , -NR3R1, -NR 3 C(O)NR4R5, -OC(O)R 3 , or -(CH 2 ) S NR 3 R4; where R 3 , P and R 5 are the same or different, each independently being selected from H and C ⁇ -6 alkyl; and s is an integer from 1 to
  • A is phenyl or naphthyl; where R 2 is straight or branched-chain C ⁇ -6 alkyl, C 2 . 6 alkenyl, C 2- alkynyl, C ⁇ -6 alkoxy, C ⁇ -6 aminoalkyl, C ⁇ -6 haloalkyl, C ⁇ -6 alkoxycarbonyl, -CN, -CF 3 , -OH, -COR 3 , -NHR 3 , -NHC(O)R 3 , -C(O)NR 3 R 4 , -NR 3 R 4 , -NR 3 C(O)NR4R 5 , -OC(O)R 3 , or -CH 2 ) q NR 3 R 4 ; where q is an integer from 1 to 6; or
  • A is aryl comprising 1 or more heteroatoms selected from N, S and O;
  • R 2 is H, halo, straight or branched-chain C ⁇ . 6 alkyl, C 2-6 alkenyl, C 2 . alkynyl, C ⁇ -6 alkoxy, C ⁇ -6 heteroalkyl, C ⁇ -6 aminoalkyl, C ⁇ -6 haloalkyl, C ⁇ - alkoxycarbonyl, -CN, - CF 3 , OH, -COR3, -NHR 3 , -NHC(O)R 3 , -C(O)NR 3 Rt, -NR3R,, -NR 3 C(O)NR4R 5 , - OC(O)R 3 or -(CH 2 ) q NR 3 R4; or a pharmaceutically acceptable salt, ester or prodrug thereof.
  • the compound is of the formula (II):
  • Preferred subgeneric embodiments of compounds of formula (II) include compounds of formulas (Ila) and (lib):
  • t is 1 and Y is -C(O)-, -NHC(O)-, S, O or -OC(O)-.
  • X 3 is C.
  • Ri is alkyl, where preferably R 2 is alkyl, aminoalkyl, alkoxy or hydroxyl. In one embodiment, p is 3. In another. Ri is C 2 . 8 alkyl and R 2 is methyl, hydroxyl or alkoxy.
  • n is 1 or 2; Y is -C(O)- or O and t is 1.
  • R 2 is halo.
  • X 3 may also be N, where according to one embodiment, Ri is alkyl or alkoxy; or Ri is benzyl or phenyl; where R 2 is alkyl or alkoxy.
  • X 3 is O, where t may be, for example, 0.
  • R 2 is alkyl or alkoxy; or R 2 is halo.
  • Particular embodiments of the invention include: 4-Methoxy- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljpiperidine: 4-Ethoxy- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljpiperidine; 4-Propoxy- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyl]piperidine; 4-Butoxy- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljpiperidine: 4-Methoxymethyl- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljpiperidine; 4-Ethoxymethyl- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljpiperidine; 4-Propoxymethyl- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljpiperidine
  • (CH 2 ) P -Y- is -(CH 2 ) 3 -C(O)- or -(CH 2 ) 3 -S-; and Xi through X 5 are C; such that -A-
  • R 2 n and Ri are not together: o-methyl-phenyl and n-butyl, respectively; phenyl and n-butyl, respectively; or p-fluoro-phenyl and -O-(CH 2 ) 2 CH 3 , respectively).
  • the present invention further provides a method of agonizing a muscarinic receptor comprising contacting the receptor with an effective amount of a compound of formula (I), inclusive of all compounds within the scope of formula (I)(i.e., including 4-rc-Butyl- 1 -[4-phenyl-4-oxo- 1 -butyljpiperidine; 4-n-Butyl- 1 -[4-(2- methylphenyl)-4-oxo-l -butyl] piperazine; 2-[3-(3- «-Butylpiperidine)propanesulfanyl] toluene; and 4-Propyloxy- 1 -[4-(4-fluorophenyl)-4-oxo- 1 -butyljpiperidine).
  • a compound of formula (I) inclusive of all compounds within the scope of formula (I)(i.e., including 4-rc-Butyl- 1 -[4-phenyl-4-oxo- 1
  • compositions comprising an effective amount of a compound of formula (I), inclusive of all compounds within the scope of formula (I)(i.e., including - «-Butyl-l-[4-phenyl-4-oxo-l -butyljpiperidine; 4- ⁇ -Butyl- l-[4-(2-methylphenyl)-4-oxo-l-butyl]piperazine; 2-[3-(3- «-
  • Butylpiperidine propanesulfanyl] toluene; and 4-Propyloxy-l-[4-(4-fluorophenyl)-4- oxo-1 -butyljpiperidine).
  • the present invention further also provides methods of treating the symptoms of a disease or condition associated with reduced levels of acetylcholine, the method comprising administering a therapeutically effective amount of a composition described herein.
  • diseases or conditions include neurogenerative disease, cognitive impairment, age-related cognitive decline or dementia.
  • Glaucoma is a disease in which an abnormality is observed in the circulation-control mechanism of the aqueous humor filling up the anterior chamber, i.e., the space formed between the cornea and the lens. This leads to an increase in the volume of the aqueous humor and an increase in intraocular pressure, consequently leading to the visual field defect and even to loss of eyesight due to the compulsion and contraction of the papillae of the optic nerve.
  • the compounds of the present invention preferably show selective agonist activity towards the ml receptor.
  • Such an agonist is defined as a compound that increases the activity of the ml muscarinic receptor when it contacts the receptor.
  • Selectivity is defined as a property of a muscarinic ml agonist whereby an amount of agonist effective to increase the activity of the ml receptor causes little or no increase in the activity of the m3 and m5 subtypes, and preferably the m2 and m4 subtypes.
  • alkyl means a straight or branched-chain alkane group with 1-6 carbon atoms in the chain, for instance methyl, ethyl, propyl, isopropyl, n-
  • heteroalkyl is intended to indicate an alkane group containing 1 or 2 heteroatoms selected from O, S or N.
  • alkenyl means a straight or branched-chain alkene group with 2-6 carbon atoms in the chain; the term “alkynyl” is intended to indicate a straight or branched-chain alkyne group with 2-6 carbon atoms in the chain.
  • aryl and “cycloalkyl” preferably refer to mono- and bicyclic ring structures comprising 5 to 12 carbon atoms, more preferably monocyclic rings comprising 5 to 6 carbon atoms. Where such rings comprise one or more heteroatoms, selected from N, S and O, (i.e., heterocyclic rings) such rings comprise a total of 5 to 12 atoms, more preferably 5 to 6 atoms.
  • Heterocyclic rings include, but are not limited to, furyl, pyrrolyl, pyrazolyl, thienyl, imidazolyl, isoxazolyl, oxazolyl, thiazolyl, isothiazolyl, pyridyl, piperidinyl, piperazinyl, pyridazinyl, pyrimidinyl, pyrazinyl, morpholinyl, oxadiazolyl, thiadiazolyl, imidazolinyl, imidazolidinyl and the like.
  • the ring may be substituted by one or more of the groups included in the definition of R 2 above.
  • substituents C ⁇ -6 alkyl, C ⁇ -6 alkenyl, C ⁇ -6 alkynyl, C ⁇ -6 alkoxy, C ⁇ - heteroalkyl, C ⁇ -6 aminoalkyl, C ⁇ - haloalkyl or C ⁇ - 6 alkoxycarbonyl may, if present, be substituted by one or more of hydroxyl, C alkoxy, halogen, cyano, amino or nitro.
  • halogen or halo includes chlorine, fluorine, iodine and bromine.
  • the starting compound having formula (X) may be prepared by general methods of organic synthesis.
  • general methods of preparing compounds of formula (X) reference is made to Fuller, R. W. et al., J. Med. Chem. 14:322-325 (1971); Foye, W. O., et al.. J. Pharm.Sci. 68:591-595 (1979); Bossier, J. R. et al.. Chem. Abstr. 66:46195h and 67:21527a (1967); Aldous, F. A. B., J. Med. Chem. 17:1100-1111 (1974); Fuller, R. W. et al., J. Pharm. Pharmacol.
  • radiolabelled derivatives having formula (XX) may be prepared by, for example, using a tritiated reducing agent to form the reductive amination or by utilizing a l4 C-labelled starting material.
  • the compound having the formula (XXII) may be reduced with, for example, AIH 3 , diborane:methyl sulfide or other standard carbonyl reducing reagents to produce the ligand having the formula (XXX).
  • the receptor ligands having formula (XXXII) may be prepared by nucleophilic displacement of an electrophile (E) by the amino derivative (XXXI).
  • electrophiles which may be used for this purpose include halides such as I, Cl, Br, tosylate or mesylate.
  • this compound may be prepared from oxidation of an sec. alcohol with for example pyridinium chlorocromate or N- chlorosuccimmide or CrO 3 -H 2 SO or nickel peroxide or metal (Al, K) or DCC- DMSO.
  • this compound may be prepared by alkylation of an alcohol with arylhalides under for example Cu catalysis.
  • this compound may be prepared by alkylation of a thiol with arylhalides under for example Cu catalysis.
  • Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
  • suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts; and salts formed with suitable organic ligands. e.g.
  • quarternary ammonium salts examples include the acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium, carbonate, chloride, clavulanate, citrate, dihydrochloride, fumarate, gluconate, glutamate, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate.
  • lactate lactobionate, laurate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, nitrate, N-methylglucamine ammonium salt, oleate, oxalate, phosphate/diphosphate, salicylate. stearate, sulfate, succinate. tannate, tartrate, tosylate, triethiodide and valerate salt.
  • the present invention includes within its scope prodrugs of the compounds of this invention.
  • prodrugs are inactive derivatives of the compounds of this invention which are readily convertible in vivo into the required compound.
  • Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs,” ed. H. Bundgaard, Elsevier, 1985. Metabolites of these compounds include active species produced upon introduction of compounds of this invention into the biological milieu.
  • the compounds according to the invention may exist as a racemate or as enantiomers. It should be noted that all such isomers and mixtures thereof are included in the scope of the present invention. Furthermore, some of the crystalline forms for compounds of the present invention may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds of the present invention may form
  • solvates with water (i.e., hydrates) or common organic solvents. Such solvates are also included in the scope of this invention.
  • Such isomers may be separated by conventional techniques such as preparative chiral chromatography.
  • the compounds may be prepared in racemic form, or individual enantiomers may be prepared either by stereoselective synthesis or by resolution.
  • the compounds may, for example, be resolved into their component enantiomers by standard techniques, such as the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-p-toluoyl-d-tartaric acid and/or (+)-di-p-toluoyl-l-tartaric acid followed by fractional crystallization and regeneration of the free base.
  • the compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary.
  • any of the processes for preparation of the compounds of the present invention it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991.
  • the protecting groups may be removed at a convenient subsequent stage using methods known from the art.
  • Compounds of the present invention may be administered in any of the foregoing compositions and according to dosage regimens established in the art whenever specific pharmacological modification of the activity of muscarinic receptors is required.
  • compositions comprising one or more compounds of the invention together with a pharmaceutically acceptable diluent or excipient.
  • compositions are in unit dosage forms such as tablets, pills, capsules (including sustained-release or delayed-release formulations), powders, granules, elixirs, tinctures, syrups and emulsions, sterile parenteral solutions or suspensions, aerosol or liquid sprays, drops, ampoules, auto-injector devices or suppositories; for oral, parenteral (e.g. intravenous, intramuscular or subcutaneous), intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation, and may be formulated in an appropriate manner and in accordance with
  • compositions may be in sustained-release form suitable for once-weekly or once-monthly administration; for example, an insoluble salt of the active compound, such as the decanoate salt, may be adapted to provide a depot preparation for intramuscular injection.
  • suitable topical formulations for administration e.g. eye or skin or mucosa.
  • the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like.
  • suitable binders, lubricants, disintegrating agents, flavoring agents and coloring agents can also be incorporated into the mixture.
  • suitable binders include, without limitation, starch, gelatin, natural sugars such as glucose or beta-lactose, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like.
  • Lubricants used in these dosage forms include, without limitation, sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
  • Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.
  • a suitable pharmaceutical excipient e.g. such as the ones described above
  • other pharmaceutical diluents e.g. water
  • the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
  • the solid preformulation composition may then be subdivided into unit dosage forms of the type described above containing from 0.1 to about 50 mg of the active ingredient of the present invention.
  • the tablets or pills of the present composition may be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action.
  • the tablet or pill can comprise an inner core containing the active compound and an outer layer as a coating surrounding the core.
  • the outer coating may be an enteric layer which serves to resist disintegration in the stomach and permits the inner core to pass intact into the
  • compositions can be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical carriers.
  • Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate. dextran, sodium carboxymethylcellulose, gelatin. methylcellulose or polyvinyl-pyrrolidone. Other dispersing agents which may be employed include glycerin and the like.
  • sterile suspensions and solutions are desired.
  • Isotonic preparations which generally contain suitable preservatives are employed when intravenous administration is desired.
  • the compositions can also be formulated as an ophthalmic solution or suspension formation, i.e., eye drops, for ocular administration
  • the present invention also relates to a method of alleviating or treating a disease or condition in which modification of muscarinic receptor activity, in particular ml receptor activity, has a beneficial effect by administering a therapeutically effective amount of a compound of the present invention to a subject in need of such treatment.
  • diseases or conditions may, for instance arise from inadequate stimulation or activation of muscarinic receptors.
  • compounds which are selective for a particular muscarinic receptor subtype, in particular ml the problems with adverse side effects observed with the known muscarinic drugs, such as tachycardia or bradycardia or gastrointestinal effects, may substantially be avoided.
  • subject refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.
  • therapeutically effective amount means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease being treated.
  • compounds of general formula I exhibit subtype selectivity for the muscarinic ml receptor subtype.
  • the compounds exhibit selectivity for the muscarinic ml receptor subtype compared to other human G-protein coupled receptors tested including serotonin, histamine, dopamine or adrenergic receptors.
  • selectivity is that these compounds may be effective in the treatment or amelioration of a number of diseases and disorders of the central nervous system without the undesirable side effects previously observed with non- selective compounds.
  • muscarinic ml receptor subtype selectivity makes them potentially very useful in treating a number of diseases and disorders characterized by cognitive impairment such as attention deficit disorder, or neurodegenerative diseases, e.g. Alzheimer's disease, other forms of age-related cognitive decline, e.g. senile dementia, or dementia-related symptoms such as decreased motor activity, mood changes, anergia, apathy, restlessness and aggressive behavior. It is currently believed that the muscarinic ml receptor may also be involved in control of intraocular pressure, and that muscarinic ml agonists may therefore be used to treat or alleviate ocular diseases such as glaucoma.
  • cognitive impairment such as attention deficit disorder, or neurodegenerative diseases, e.g. Alzheimer's disease, other forms of age-related cognitive decline, e.g. senile dementia, or dementia-related symptoms such as decreased motor activity, mood changes, anergia, apathy, restlessness and aggressive behavior.
  • muscarinic ml receptor may also
  • compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses two, three or four times daily.
  • compounds for the present invention may be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to persons skilled in the art.
  • the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.
  • the dosage regimen utilizing the compounds of the present invention is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound employed.
  • a physician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the disease or disorder which is being treated.
  • the daily dosage of the products may be varied over a wide range from 0.01 to 100 mg per adult human per day.
  • the compositions are preferably provided in the form of tablets containing 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0 or 50.0 mg of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated.
  • a unit dose typically contains from about 0.001 mg to about 50 mg of the active ingredient, preferably from about 1 mg to about 10 mg of active ingredient.
  • An effective amount of the drug is ordinarily supplied at a dosage level of from about 0.0001 mg/kg to about 25 mg/kg of body weight per day.
  • the range is from about 0.001 to 10 mg/kg of body weight per day, and especially from about 0.001 mg/kg to 1 mg/kg of body weight per day.
  • the compounds may be administered on a regimen of 1 to 4 times per day.
  • Compounds according to the present invention may be used alone at appropriate dosages defined by routine testing in order to obtain optimal pharmacological effect on a muscarinic receptor, in particular the muscarinic ml receptor subtype, while minimizing any potential toxic or otherwise unwanted effects.
  • co-administration or sequential administration of other agents which improve the effect of the compound may, in some cases, be desirable.
  • the pharmacological properties and the selectivity of the compounds of this invention for specific muscarinic receptor subtypes may be demonstrated by a number of different assay methods using recombinant receptor subtypes, preferably of the human receptors if these are available, e.g. conventional second messenger or binding assays.
  • a particularly convenient functional assay system is the receptor selection and amplification assay disclosed in US 5,707,798 describing a method of screening for bioactive compounds by utilizing the ability of cells transfected with receptor DNA, e.g. coding for the different muscarinic subtypes, to amplify in the presence of a ligand of the receptor. Cell amplification is detected as increased levels of a marker also expressed by the cells.
  • Example I 4-n-Butyl-l-[4-(2-methylphenyl)-4-oxo-l-butyl]piperidine (5) l-Benzyl-4-n-butylidenepiperidine (2).
  • the resulting suspension was heated to 90°C for 30 min, until the evolution of hydrogen ceased.
  • the suspension was cooled on an ice-bath for 20 min followed by addition of a slurry of butyltriphenylphosphonium bromide (26.6 g, 67 mmol) in DMSO (70 mL).
  • Example II 3-Hydroxymethyl-[4-(2-methylphenyl)-4-oxo-l-butyl]piperidine (7) 4-(3-Hydroxymethyl-piperidin-l-yl)-butyronitrile (6).
  • piperidine-3-yl-methanol (1.12 g, 10 mmol) in acetonitrile (10 mL)
  • potassium carbonate (1.38 g, 10 mmol
  • 4- bromobutyronitrile (0.90 mL, 9 mmol).
  • the reaction mixture was stirred at rt. for 12 h.
  • the mixture was filtered and evaporated to dryness.
  • reaction mixture was quenched by addition of H 2 SO (10 mL, 2 M) and stirred at rt for 12 hours followed by addition of NaOH (10 mL, 2 M).
  • Addition of THF (15 mL) was followed by extraction with ethyl acetate (3 x 50 mL) and the combined organic phases are washed with brine (10 mL) and NaOH (10 mL, 2 M), dried (MgS0 4 ) and evaporated to dryness to produce 0.43 g of crude 9.
  • Example VII 4-Methyl-l-[4-(2-methylphenyl)4-oxo-l-butyl]piperazine (15) 4-(4-Methyl-piperazin-l-yl)-butyronitrile (14).
  • 1- methyl-piperazine 0.52 g, 5.1 mmol
  • 4-bromobutyronitrile 0.78 g, 5.3 mmol
  • potassium carbonate 0.71 g, 5.3 mmol
  • Example IX 4-n-Butyl-l-[4-(2-ethoxyphenyl)-4-oxo-l-butylJpiperidine (18)
  • Mg turnings 94 mg, 3.8 mmol
  • Et 2 0 3 mL
  • reaction mixture was quenched by addition of H 2 S0 (7 mL, 2 M) and stirred at rt for 3 hours, followed by addition of NaOH (20 mL, 2 M) until basic conditions.
  • the reaction mixture was extracted with ethyl acetate (3 x 50 mL) and the combined organic phases are washed with brine (10 mL) and NaOH (10 mL, 2 M), and the organic phases were dried (MgS0 4 ) and evaporated to dryness to produce 0.69 g of crude 19.
  • the crude product was subjected to CC [eluent: CH 2 C1 2 : MeOH (99:1)] to give pure 19 (0.40 g, 64 %); LC-MS [M + H] + 315 (cald. 315.5).
  • reaction mixture was quenched by addition of H 2 S0 (8 mL, 2 M) and stirred at rt for 4 hours, then the reaction mixture was basified by addition of NaOH (20 mL, 2 M).
  • Addition of THF (20 mL) was followed by extraction with ethyl acetate (3 x 50 mL) and the combined organic phases are washed with brine (10 mL) and NaOH (10 mL, 2 M), and the organic phases were dried (MgS0 ) and evaporated to dryness to produce 0.61 g of crude 20.
  • the crude product was subjected to CC [eluent: CH 2 C1 2 : MeOH (99:1)] to give pure 20 (0.21 g, 35 %); LC-MS [M+ Hf 315 (cald. 315.5).
  • the reaction mixture was basified by addition of NaOH (2 mL, 2.0 M) and filtered through celite.
  • the aqueous phase was extracted with ethyl acetate (3 x 50 mL) and the combined organic phases were washed with brine (10 mL) and NaOH (10 mL, 2 M), dried (MgS0 4 ) and evaporated to dryness to produce 0.42 g of crude 27.
  • the crude product was subjected to CC [eluent: : CH 2 C1 2 : MeOH (99:1)] to give pure 27 (0.21 g, 58 %); LC-MS [M+ H] + 303 (cald. 303.2).
  • NIH 3T3 cells available from the American Type Culture Collection as ATCC CRL 1658
  • NIH 3T3 cells were grown at 37°C in a humidified atmosphere (5% C0 2 ) incubator in Dulbecco ' s modified Eagle's medium (DMEM) supplemented with 4.5 g/1 glucose, 4 mM glutamine, 50 units/ml penicillin, 50 units/ml streptomycin (available from Advanced Biotechnologies, Inc., Gaithersburg, MD) and 10% calf serum (available from Sigma, St. Louis, MI).
  • DMEM Dulbecco ' s modified Eagle's medium
  • the cells were treated with trypsin-EDTA, spun down and plated at 2xl0 6 per 15 cm dish in 20 ml of DMEM containing 10% calf serum.
  • the ml-m5 muscarinic receptor subtypes were cloned substantially as described by Bonner et al., Science 237, 1987, p. 527, and Bonner et al., Neuron 1, 1988, p. 403.
  • the cells were co-transfected with DNA encoding a chimera between the Gq protein and the five carboxy-terminal amino acids of the Gi protein (the Gq-i5 construct is described by Conklin et al., Nature 363, 1993, p.274).
  • the cells were transfected using the Superfect transfection reagent (available from Qiagen, Valencia, CA) in accordance with the manufacturer's instructions.
  • 60 ⁇ l Superfect was added to the DNA and mixed thoroughly by pipetting up and down several times. The mixture was incubated at room temperature for 10-15 minutes.
  • the media were aspirated, and 12 ml fresh DMEM containing 10% calf serum and 50 units/ml penicillin/streptomycin was added to the plates.
  • the DNA-Superfect solution was mixed once more with a pipette and added to the plate which was swirled to distribute the DNA mixture evenly over the surface.
  • the cells were incubated overnight at 37°C and 5% C0 2 .
  • the media were aspirated and the plates were rinsed once with a 15 ml volume of Hank's Buffered Saline. The plates were swirled to ensure thorough rinsing. 20 ml fresh DMEM supplemented with 10% calf serum and 50 units/ml penicillin/streptomycin was added to the plates. The cells were incubated for 24-48 hours until the plates were 100% confluent.
  • DMEM containing 2% Cyto-SF3 was heated at 37°C in a water bath under sterile conditions.
  • Sterile working stock solutions of test compounds to be assayed were prepared by diluting the compounds in DMEM to 8x the final concentration for testing.
  • the compound (carbachol) to be included in the assay as a positive control was also diluted in DMEM to 8x the final concentration.
  • 50 ⁇ l of the DMEM containing 2% Cyto-SF3 was added to each well of 96-well microtiter plates under sterile conditions.
  • HBS Hank's Buffered Saline
  • the plates were rinsed with this medium, and the cells were pipetted into a tube.
  • the cells were centrifuged at 1000 rpm for 5-10 min. in an IEC Centra CL2 centrifuge (produced by Sorvall). Afterwards, the medium was carefully aspirated so as not to dislodge the cells.
  • the cell pellet was suspended in 1600 ⁇ l DMEM containing 10% calf serum and 50 units/ml penicillin and 50 units/ml streptomycin, after which 20 ml DMEM supplemented with 2% Cyto-SF3 was added. 50 ⁇ l aliquots of this cell suspension was added to the wells of the 96-well microtiter plates prepared above (except for the plate control wells). The plates were then incubated for 4 days at 37°C and 5% C0 2 .
  • NIH 3T3 cells were co- transfected with DNAs encoding the ml, m3 and m5 receptor subtypes.
  • a compound library containing approximately 35,000 small organic compounds (1 per well) was screened against the receptors by the procedures described above.
  • Fig. 1 illustrates data from one 96-well plate from the screen. On this plate, two compounds were active at one or more of the transfected receptors. In the total screen, four related compounds were identified that showed activity. To determine which of the receptors were activated in the screen, the compounds were tested as described above against each of the receptors transfected into separate cell cultures. Compound A only activated the ml receptor subtype, at which it was a potent partial agonist, inducing a lower maximal response than the reference compound carbachol.
  • the four compounds were found to selectively activate the ml receptor with no significant activity at the m2, m3, m4 or m5 muscarinic receptors.
  • the most active compound, compound A was not an antagonist of carbachol-induced responses of the five muscarinic receptor subtypes.
  • Compound A was further tested for agonist activity against several other receptors at the ⁇ -adrenergic receptor subtypes ID, IB, 1A, 2A, 2B and 2C, the histamine HI and the serotonin 5-HT1A and 5-HT2A subtypes. The compound showed no significant activity in these assays. In antagonist experiments, compound A did not inhibit responses of the ⁇ -adrenergic receptor subtypes 2 A, 2B or 2C, or the serotonin receptor subtypes 5-HT1A or 5-HT2A. As illustrated in Figure 2, the responses induced by compound A were blocked by the muscarinic antagonist atropine with the same potency as were responses induced by the muscarinic agonist carbachol.
  • R-SAT assays (see U.S. patent no. 5,707,798, incorporated herein by reference) were carried out where cells transfected with ml, m3 or m5 receptors were exposed to seven compounds at 1.5 ⁇ M concentration. Cellular response is expressed as a percentage of the maximum response of the cells (defined as response to 10 ⁇ M carbachol). The results are presented in the following table.
  • the compounds are selective agonists of the ml receptor.

Abstract

Compounds and methods are provided for the alleviation or treatment of diseases or conditions in which modification of muscarinic m1 receptor activity has a beneficial effect. In the method, a therapeutically effective amount of a selective muscarinic m1 agonist compound is administered to a patient in need of such treatment.

Description

COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS
Field of the Invention
The present invention relates to novel compounds which are selective for muscarinic acetylcholine receptor subtypes, as well as to methods for activating muscarinic receptors and for treating or alleviating diseases in which modification of muscarinic receptor activity is beneficial.
Background of the Invention
Muscarinic acetylcholine receptors play a central role in the central nervous system for higher cognitive functions, as well as in the peripheral parasympathetic nervous system. Cloning has established the presence of five distinct muscarinic receptor subtypes (termed ml-m5) (cf. T.I. Bonner et al, Science 237, 1987, pp. 527- 532; T.I. Bonner et al., Neuron 1, 1988, pp. 403-410). It has been found that ml is the predominant subtype in the cerebral cortex and is believed to be involved in the control of cognitive functions, m2 is predominant in heart and is believed to be involved in the control of heart rate, m3 is believed to be involved in gastrointestinal and urinary tract stimulation as well as sweating and salivation, m4 is present in brain, and m5 is present in brain and may be involved certain functions of the central nervous system associated with the dopaminergic system.
Animal studies of various muscarinic ligands (S. Iversen, Life Sciences 60 (Nos. 13/14), 1997, pp. 1 145-1152) have shown that muscarinic compounds have a profound effect on cognitive functions, e.g. learning and memory. This would suggest a potential utility of muscarinic agonists in the improvement of cognitive functions in diseases characterized by cognitive impairment, both age-related (such as Alzheimer's disease or other dementias) and not age-related (such as attention deficit hyperactivity disorder). Based on the presence of muscarinic receptor subtypes in various tissues, it would appear that the ml receptor subtype is the more abundant one in the cerebral cortex, basal ganglia and hippocampus where it accounts for 35-60% of all muscarinic receptor binding sites (cf. A. Levey, Proc. Natl. Acad. Sci.. USA 93, 1996, pp. 13541- 13546). It has been proposed that the ml (and possibly m4) subtype plays a major role as a postsynaptic muscarinic receptor (located on cholinoceptive neurons in the neocortex and hippocampus) in various cognitive and motor functions and is likely to be a major contributor to the ml responses measured in these regions of the brain. It has previously been found that conditions associated with cognitive impairment, such as Alzheimer's disease, are accompanied by selective loss of acetylcholine in the brain. This is believed to be the result of degeneration of cholinergic neurons in the basal forebrain which innervate areas of the association cortex and hippocampus involved in higher processes (cf. S. Iversen, supra). This finding would suggest that such conditions may be treated or at least ameliorated with drugs that augment the cholinergic function in the affected areas of the brain.
Treatment with acetylcholine esterase (AChE) inhibitors such as 9-amino-l,2,3,4- tetrahydroacridine (tacrine) results in an increase of acetylcholine in the brain which indirectly causes stimulation of muscarinic receptors. Tacrine treatment has resulted in a moderate and temporary cognitive improvement in Alzheimer's patients (cf. Kasa et al., supra). On the other hand, tacrine has been found to have cholinergic side effects due to the peripheral acetylcholine stimulation. These include abdominal cramps, nausea, vomiting, diarrhea, anorexia, weight loss, myopathy and depression. Gastrointestinal side effects have been observed in about a third of the patients treated. Tacrine has also been found to cause significant hepatotoxicity, elevated liver transaminases having been observed in about 30% of the patients (cf. P. Taylor, "Anticholinergic Agents". Chapter 8 in Goodman and Gilman: The Pharmacological Basis of Therapeutics, 9th Ed., 1996, pp. 161-176). The adverse effects of tacrine have severely limited its clinical utility. Another AChE inhibitor, (R,S)-l-benzyl-4-[5,6- dimethoxy-l-indanon-2yl]methylpiperidine.HCl (donepezil), has recently been approved for the treatment of symptoms of mild to moderate Alzheimer's disease (cf. P. Kasa et al, supra). No hepatic damage has been observed for this compound but it has gastrointestinal effects similar to those of tacrine, probably due to stimulation of the m3 receptor caused by elevated parasympathetic tone.
It has previously been suggested that, since the muscarinic ml receptors in the prefrontal cortex and hippocampus appear to be intact, it may be possible to remedy or at least ameliorate the loss of acetylcholine in Alzheimer's disease patients by administration of drugs acting as agonists on those muscarinic receptors (cf. J.H. Brown and P. Taylor, "Muscarinic Receptor Agonists and Antagonists", Chapter 7 in
- 2 - Goodman and Gilman: The Pharmacological Basis of Therapeutics, 9th Ed., 1996, p. 147).
The muscarinic agonists (believed to be ml selective) hitherto suggested for the treatment of Alzheimer's disease, such as arecoline, have not shown greater efficacy in clinical trials than AChE inhibitors (cf. S.V.P. Jones et al., supra). In one study (cf. T. Sunderland et al., Brain Res. Rev. 13, 1988, pp. 371-389), arecoline was found to have not so much cognitive enhancing effects as effects on behavioral changes often observed in Alzheimer's disease patients, such as a significant increase in motor activity, significant uplifting of mood, and significant decrease in anergia. However, presumed ml agonists have later been found to be weak partial agonists selective for the m2 and/or m3 receptor subtypes (H. Brauner-Osborne et al., J. Med. Chem. 38, 1995, pp. 2188-2195). As indicated above, m2 subtype selectivity is presumed to be responsible for the cardiovascular effects observed for these agonists, e.g. tachycardia and bradycardia, and m3 activity is believed to account for the adverse gastrointestinal effects of the agonists. m2 and/or m3 activity is therefore a significant drawback for the muscarinic agonists proposed until now for the treatment of Alzheimer's disease, severely limiting the doses of the drugs which it has been possible to administer to patients who may therefore have received sub-optimal doses. Furthermore, the lack of subtype selectivity and low potency of the currently tested cholinergic compounds appear to favor the negative peripheral side effects and have limited cognitive effects because of weak and/or opposing actions in the brain. It would therefore be of great advantage to develop compounds which have an improved selectivity for the ml subtype, but which have little or no activity on the m2 and m3 subtypes.
- 3 - Summary of the Invention
The present invention provides compounds with muscarinic agonist activity of the general formula (I):
X / (R2)n
X3^ 4 ~ (X5)k A
(R.X ^ ^- ^ (CH2)P Y
wherein Xi, X2, X3, X4 and X5 are selected from C, N and O; k is 0 or 1; t is 0, 1 or 2;
Ri is straight or branched-chain d-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, Cι-8 alkylidene, Cι- alkoxy, Cι-8 heteroalkyl, Cι-8 aminoalkyl, Cι-8 haloalkyl, Cι-8 alkoxycarbonyl, Cι-8 hydroxyalkoxy, Cι-8 hydroxyalkyl, -SH, Cι-8 alkylthio, -O-CH2-
C5-6 aryl,
-C(O)-C5-6 aryl substituted with Cι-3 alkyl or halo; C5-6 aryl or C5-6 cycloalkyl optionally comprising 1 or more heteroatoms selected from N, S and O; -C(O)NR3R4,
-NR3R*, -NR3C(O)NR4R5, -CR3R4, -OC(O)R3, -(O)(CH2)sNR3R4 or -(CH2)sNR3R4; where R3,
R4 and R are the same or different, each independently being selected from H, Cι-6 alkyl; C5-6 aryl optionally comprising 1 or more heteroatoms selected from N, O and
S, and optionally substituted with halo or Cι- alkyl; C3-6 cycloalkyl; or R3 and R4 together with the N atom, when present, form a cyclic ring structure comprising 5-6 atoms selected from C, N, S and O; and s is an integer from 0 to 8;
A is C5-ι2 aryl or C5- cycloalkyl, each optionally comprising 1 or more heteroatoms selected from N, S and O;
R2 is H, amino, hydroxyl, halo, or straight or branched-chain Cι-6 alkyl, C -6 alkenyl, C2-6 alkynyl, Cι- alkoxy, Cι- heteroalkyl, Cι-6 aminoalkyl, Cι- haloalkyl, C1.6 alkylthio, Cι-6 alkoxycarbonyl, -CN, -CF3, -OR3, -COR3, NO2, -NHR3, - NHC(O)R3, -C(O)NR3R4, -NR3R1, -NR3C(O)NR4R5, -OC(O)R3, -C(O)R3R4, -O(CH2)qNR3, -CNR3 t or -(CH2)qNR3R4; where q is an integer from 1 to 6; n is 0, 1, 2, 3 or 4, the groups R , when n > 1, being the same or different; p is 0 or an integer from 1 to 5;
- 4 - Y is O, S, CHOH, -NHC(O)-, -C(O)NH-, -C(O)-, -OC(O)-, NR7 or -CH=N-. and R7 is H or C alkyl; or absent; and
Z is CR8R9 wherein R8 and R are independently selected from H, and straight or branched chain Cι.8 alkyl; or a pharmaceutically acceptable salt, ester or prodrug thereof.
The present invention further provides pharmaceutical compositions comprising an effective amount of a compound of formula (I).
Further provided are methods of treating the symptoms of a disease or condition associated with reduced levels of acetylcholine, said method comprising administering a therapeutically effective amount of a composition comprising a compound of formula (I).
In yet a further embodiment, the present invention provides a method of treating the symptoms of a disease or condition associated with increased intraocular pressure. such as, for example, glaucoma, where the method comprises administering a therapeutically effective amount of a composition comprising a compound of formula
(D-
Brief Description of the Drawings
Figure 1 is a graph showing raw data from one 96-well microtiter plate of screening of 35,000 small organic molecules in the assay described in Example XVI. Figure 2 is a graph showing data comparing the profile of the reference antagonist atropine with ml muscarinic receptor transfected cells stimulated with either carbachol (open triangles) or compound A (Example I) (closed triangles).
Detailed Description of the Invention
The present invention provides compounds preferably showing a relatively high selectivity towards the ml receptor subtype relative to other muscarinic subtypes which may have a beneficial effect in the treatment of cognitive impairment such as Alzheimer's disease or other conditions associated with age-related cognitive decline while avoiding the adverse affects of the drugs hitherto suggested for this purpose. Compounds exhibiting this property have surprisingly been isolated by screening against ml-m5 receptor subtypes.
According to one embodiment, the present invention provides compounds of formula (I), wherein
- 5 - Xi, X2, X3, X4 and X5 are C; or one of Xi, X2, X3, X4 or X5 is O or N and the others are C; k is 0 or 1 ; t is 1; Ri is straight or branched-chain Cι-8 alkyl, C2-8 alkenyl, C -8 alkynyl, Cι-8 alkylidene, Cι-8 alkoxy, Cι-8 aminoalkyl, Cι-8 haloalkyl, Cι-8 alkoxycarbonyl, -C(O)NR3R4, -NR3R1, -NR3C(O)NR4R5, -OC(O)R3, or -(CH2)SNR3R4; where R3, P and R5 are the same or different, each independently being selected from H and Cι-6 alkyl; and s is an integer from 1 to 8; n is 1, 2 or 3; and
A is phenyl or naphthyl; where R2 is straight or branched-chain Cι-6 alkyl, C2.6 alkenyl, C2- alkynyl, Cι-6 alkoxy, Cι-6 aminoalkyl, Cι-6 haloalkyl, Cι-6 alkoxycarbonyl, -CN, -CF3, -OH, -COR3, -NHR3, -NHC(O)R3, -C(O)NR3R4, -NR3R4, -NR3C(O)NR4R5, -OC(O)R3, or -CH2)qNR3R4; where q is an integer from 1 to 6; or
A is aryl comprising 1 or more heteroatoms selected from N, S and O;
R2 is H, halo, straight or branched-chain Cι.6 alkyl, C2-6 alkenyl, C2. alkynyl, Cι-6 alkoxy, Cι-6 heteroalkyl, Cι-6 aminoalkyl, Cι-6 haloalkyl, Cι- alkoxycarbonyl, -CN, - CF3, OH, -COR3, -NHR3, -NHC(O)R3, -C(O)NR3Rt, -NR3R,, -NR3C(O)NR4R5, - OC(O)R3 or -(CH2)qNR3R4; or a pharmaceutically acceptable salt, ester or prodrug thereof.
In one preferred embodiment, the compound is of the formula (II):
(Rl . (R2)n
K N— (CH^-Y- II
Preferred subgeneric embodiments of compounds of formula (II) include compounds of formulas (Ila) and (lib):
- 6 - R,
(R.X
x N— (CH2)p-Y- Ila
R
(R.X 2.
X v N— (CH2)P-Y— Kb
According to one preferred series of embodiments of compounds of formulas I, II, Ila and lib, t is 1 and Y is -C(O)-, -NHC(O)-, S, O or -OC(O)-. In another, X3 is C. Preferably, Ri is alkyl, where preferably R2 is alkyl, aminoalkyl, alkoxy or hydroxyl. In one embodiment, p is 3. In another. Ri is C2.8 alkyl and R2 is methyl, hydroxyl or alkoxy.
In one embodiment, n is 1 or 2; Y is -C(O)- or O and t is 1. Preferably, R2 is halo. According to other embodiments, t is 0; or Ri is alkoxy, benzyl or phenyl.
X3 may also be N, where according to one embodiment, Ri is alkyl or alkoxy; or Ri is benzyl or phenyl; where R2 is alkyl or alkoxy.
According to another embodiment, X3 is O, where t may be, for example, 0. Preferably, R2 is alkyl or alkoxy; or R2 is halo.
Particular embodiments of the invention include: 4-Methoxy- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljpiperidine: 4-Ethoxy- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljpiperidine; 4-Propoxy- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyl]piperidine; 4-Butoxy- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljpiperidine: 4-Methoxymethyl- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljpiperidine; 4-Ethoxymethyl- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljpiperidine; 4-Propoxymethyl- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljpiperidine; 4-(2-Methoxyethyl)-l-[4-(2-methylphenyl)-4-oxo-l-butyl]piperidine; 4-(2-Ethoxyethyl)- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljpiperidine; 4-Methoxy-4-methyl-l-[4-(2-methylphenyl)-4-oxo-l-butyljpiperidine; 4-Methoxy-4-ethyl- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljpiperidine; 4-Methoxy-4-propyl- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljpiperidine;
- 7 - 4-Methoxy-4-«-butyl- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljpiperidine;
4-Ethoxy-4-methyl- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljpiperidine; .
4-Ethoxy-4-ethyl-l-[4-(2-methylphenyl)-4-oxo-l -butyljpiperidine;
4-Ethoxy-4-propyl- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljpiperidine; 4-Ethoxy-4-n-butyl- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljpiperidine;
4-Propoxy-4-methyl- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljpiperidine;
4-Propoxy-4-ethyl- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljpiperidine;
4-Propoxy-4-propyl- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljpiperidine;
4-Propoxy-4-«-butyl- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljpiperidine; 4-tt-Butoxy-4-methyl- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljpiperidine;
4-π-Butoxy-4-ethyl-l-[4-(2-methylphenyl)-4-oxo-l -butyljpiperidine;
4-π-Butoxy-4-propyl- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljpiperidine;
4-π-Butoxy-4-«-butyl-l-[4-(2-methylphenyl)-4-oxo-l -butyljpiperidine;
2-[3-(4-tt-Butylpiperidine)propoxyjtoluene; 2-[3-(4-/?-Butylpiperidine)propanesulfanyl]toluene;
2-[3-(4-«-Butylpiperidine)propanesulfιnyljtoluene;
3-(4-«-Butylpiperidine)-o-tolyl-butane- 1 -thione;
3-(4-«-Butylpiperidinopropyl)-o-tolyl-amine;
N-(4-(4-n-Butylpiperidine)- 1 - -tolyl-butyl)-hydroxylamine; 4-«-Butyl- 1 -[4-(2-chlorophenyl)-4-oxo- 1 -butyljpiperidine;
4-π-Butyl- 1 -[4-(2-bromophenyl)-4-oxo- 1 -butyljpiperidine;
4-«-Butyl- 1 -[4-(2-fluorophenyl)-4-oxo- 1 -butyljpiperidine;
4-n-Butyl- 1 -[4-(2-mercaptophenyl)-4-oxo- 1 -butyljpiperidine;
4-rc-Butyl- 1 -[4-(2-sulfanylmethylphenyl)-4-oxo- 1 -butyljpiperidine; 4-n-Butyl-l-[4-(2-sulfanylethylphenyl)-4-oxo-l -butyljpiperidine;
4-«-Butyl-l -[4-(2-aminophenyl)-4-oxo- 1 -butyljpiperidine;
4-rc-Butyl- 1 -[4-(2-methylaminophenyl)-4-oxo- 1 -butyljpiperidine;
4-«-Butyl- 1 -[4-(2-ethylaminophenyl)-4-oxo- 1 -butyljpiperidine;
4-rc-Butyl- 1 -[4-(2-dimethylaminophenyl)-4-oxo- 1 -butyljpiperidine; 4-«-Butyl-l-[4-(2-diethylaminophenyl)-4-oxo-l -butyljpiperidine;
4-rc-Butyl- 1 -[4-( 1 -H-imidazol-2-yl)-4-oxo- 1 -butyljpiperidine;
4-«-Butyl- 1 -[4-( 1 -imidazol- 1 -yl)-4-oxo- 1 -butyljpiperidine; 4-«-Buty 1- 1 - [4-( 1 -thiazol-2-yl)-4-oxo- 1 -butyljpiperidine;
4-π-Butyl- 1 -[4-([ 1 ,2,3 jtriazol- 1 -yl)-4-oxo- 1 -butyljpiperidine; 2-[4-«-butyl-piperidine-l-ethylj-8-methyl-3,4-dihydro-2H-naphthalen-l-one:
2-[4-«-butyl-piperidine- 1 -ethyl] -7-methyl-indan- 1 -one;
3-[4-rc-butyl-piperidine- 1 -ethylj-chroman-4-one;
2-[4-/7-butyl-piperidine-l-ethyl]-lH-benzoimidazole; 4-n-Butyl- 1 -[4-(4-fluoro-2-methylphenyl)-4-oxo- 1 -butyljpiperidine;
4-«-Butyl- 1 -[4-(2-hydroxyphenyl)-4-oxo- 1 -butyljpiperidine;
4-w-Butyl- 1 -[4-(2-methoxyphenyl)-4-oxo- 1 -butyljpiperidine;
4-w-Butyl- 1 - [4-( 1 -thiophen-2-yl)-4-oxo- 1 -butyljpiperidine;
4-«-Butyl- 1 -[4-(2-ethylphenyl)-4-oxo- 1 -butyljpiperidine; 4-M-Butyl- 1 -[4-(2-ethoxyphenyl)-4-oxo- 1 -butyljpiperidine;
4-«-Butyl- 1 -[4-(2,4-dimethylphenyl)-4-oxo- 1 -butyljpiperidine;
4-tt-Butyl- 1 -[4-(2,3-dimethylphenyl)-4-oxo- 1 -butyljpiperidine;
4-n-Butyl- 1 - [4-(3 -methoxypheny l)-4-oxo- 1 -butyljpiperidine;
4-tt-Butyl- 1 -[4-(2-benzyloxyphenyl)-4-oxo- 1 -butyljpiperidine; 4-rø-Butyl- 1 -[4-(4-methylphenyl)-4-oxo- 1 -butyljpiperidine;
4-tt-Butyl-N-phenyl-butyramide;
4-Methyl-l-[4-(2-methylphenyl)-4-oxo-l -butyljpiperidine;
4-n-Butyl- 1 -[4-(naphthalen- 1 -yl)-4-oxo- 1 -butyljpiperidine;
4-Benzyl- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljpiperidine; 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljpyrrolidine;
4-Benzyl- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljpiperazine;
2-Propyl- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljpiperidine;
2-Ethyl- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljpiperidine;
4-n-Propyl- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljpiperazine; 3 ,5-Dimethyl- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljpiperidine;
4-Methyl-l-[4-(2-methylphenyl)-4-oxo-l -butyljpiperazine;
4-n-Hexyl- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljpiperazine;
4-Hydroxyethyl-l-[4-(2-methylphenyl)-4-oxo-l -butyljpiperazine;
4-Ethyl-l-[4-(2-methylphenyl)-4-oxo-l -butyljpiperazine; 4-Benzyl- 1 -[4-(4-fluorophenyl)-4-oxo- 1 -butyljpiperidine;
4-Benzyl-l-[4-(4-bromophenyl)-4-oxo-l -butyljpiperidine;
4-Phenyl- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljpiperazine;
3-Hydroxymethyl- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljpiperidine;
4-Methyl- 1 -[4-(4-bromophenyl)-4-oxo- 1 -butyljpiperidine;
- 9 - 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljpiperidine;
2-Hydroxymethyl- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljpiperidine; .
4-Benzyl- 1 -[4-(2-methylphenyl)-4-oxo- 1 -pentyljpiperazine;
4-tt-Hexyl-l-[4-(2-methylphenyl)-4-oxo-l -pentyljpiperazine; 4-(Piperidine- 1 -yl)- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljpiperidine;
1 -[4-(2-methylphenyl)-4-oxo- 1 -butylj-2,3-dihydro- 1 H-indole;
4-Benzyl-l-[5-(2-methylphenyl)-5-oxo-l-pentyljpiperidine;
4-M-Butyl- 1 -[5-(2-methylphenyl)-5-oxo- 1 -pentyljpiperidine;
4-«-Butyl- 1 -[4-(2,6-dimethylphenyl)-4-oxo- 1 -butyljpiperidine; 4-«-Butyl-l-[4-(2-methoxymethylphenyl)-4-oxo-l -butyljpiperidine;
1 -(2-Methylphenyl)-2-(4-benzylpiperazin- 1 -yl)-ethanone;
3,5-Dimethyl-l-[5-(2-methylphenyl)-5-oxo-l-pentyl]piperidine;
3,5-Dimethyl - 1 -[4-(4-fluorophenyl)-4-oxo- 1 -butyljpiperidine;
1 -[4-(4-Fluorophenyl)-4-oxo- 1 -butyljpyrrolidine; 4-Benzyl- 1 -[6-(2-methylphenyl)-6-oxo- 1 -hexyl jpiperazine;
3 ,5-Dimethyl - 1 -[6-(2-methylphenyl)-6-oxo- 1 -butyljpiperidine;
4-Benzyl- 1 -[5-(2-methoxyphenyl)-5-oxo- 1 -pentyljpiperazine;
4-Benzyl- 1 - [3 -phenyl-3 -oxo- 1 -propyl jpiperazine;
4-«-Butyl-l-[5-(2-methoxyphenyl)-5-oxo-l-pentyljpiperidine; 3,5-Dimethyl-l-[4-(4-fluoro-2-methylphenyl)-4-oxo-l -butyljpiperidine;
3-n-Butyl- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljazetidine;
4-π-Butyl- 1 -[4-(2-methylphenyl)-4-oxo-2 -methyl- 1 -butyljpiperidine;
4-/7-Butyl-l-[4-(2-methylphenyl)-4-oxo-2,2-dimethyl-l -butyljpiperidine;
4-tt-Butyl- 1 -[4-(2-methylphenyl)-4-oxo-2-ethyl- 1 -butyljpiperidine; 4-rø-Butyl- 1 -[4-(2-methylphenyl)-4-oxo-2-propyl- 1 -butyljpiperidine; and
4-«-Butyl- 1 -[4-(2-methylphenyl)-4-oxo-2,2-diethyl- 1 -butyljpiperidine.
Compounds per se specifically excluded from the scope of formula I are A-n-
Butyl- 1 -[4-phenyl-4-oxo- 1 -butyljpiperidine; 4-/?-Butyl- 1 -[4-(2-methylphenyl)-4-oxo-
1 -butyl] piperazine; 2-[3-(3-«-Butylpiperidine)propanesulfanyl]toluene; and 4- Propyloxy-l-[4-(4-fluorophenyl)-4-oxo-l -butyljpiperidine (i.e., compounds where -
(CH2)P-Y- is -(CH2)3-C(O)- or -(CH2)3-S-; and Xi through X5 are C; such that -A-
(R2)n and Ri are not together: o-methyl-phenyl and n-butyl, respectively; phenyl and n-butyl, respectively; or p-fluoro-phenyl and -O-(CH2)2CH3, respectively).
- 10 - The present invention further provides a method of agonizing a muscarinic receptor comprising contacting the receptor with an effective amount of a compound of formula (I), inclusive of all compounds within the scope of formula (I)(i.e., including 4-rc-Butyl- 1 -[4-phenyl-4-oxo- 1 -butyljpiperidine; 4-n-Butyl- 1 -[4-(2- methylphenyl)-4-oxo-l -butyl] piperazine; 2-[3-(3-«-Butylpiperidine)propanesulfanyl] toluene; and 4-Propyloxy- 1 -[4-(4-fluorophenyl)-4-oxo- 1 -butyljpiperidine).
The present further provides pharmaceutical compositions comprising an effective amount of a compound of formula (I), inclusive of all compounds within the scope of formula (I)(i.e., including -«-Butyl-l-[4-phenyl-4-oxo-l -butyljpiperidine; 4-π-Butyl- l-[4-(2-methylphenyl)-4-oxo-l-butyl]piperazine; 2-[3-(3-«-
Butylpiperidine)propanesulfanyl] toluene; and 4-Propyloxy-l-[4-(4-fluorophenyl)-4- oxo-1 -butyljpiperidine).
The present invention further also provides methods of treating the symptoms of a disease or condition associated with reduced levels of acetylcholine, the method comprising administering a therapeutically effective amount of a composition described herein. Exemplary diseases or conditions include neurogenerative disease, cognitive impairment, age-related cognitive decline or dementia.
The compounds of the present invention have also demonstrated the ability to reduce intraocular pressure, and therefore can be used in treatment of such diseases as glaucoma. Glaucoma is a disease in which an abnormality is observed in the circulation-control mechanism of the aqueous humor filling up the anterior chamber, i.e., the space formed between the cornea and the lens. This leads to an increase in the volume of the aqueous humor and an increase in intraocular pressure, consequently leading to the visual field defect and even to loss of eyesight due to the compulsion and contraction of the papillae of the optic nerve.
The compounds of the present invention preferably show selective agonist activity towards the ml receptor. Such an agonist is defined as a compound that increases the activity of the ml muscarinic receptor when it contacts the receptor. Selectivity is defined as a property of a muscarinic ml agonist whereby an amount of agonist effective to increase the activity of the ml receptor causes little or no increase in the activity of the m3 and m5 subtypes, and preferably the m2 and m4 subtypes.
As used herein, the term "alkyl" means a straight or branched-chain alkane group with 1-6 carbon atoms in the chain, for instance methyl, ethyl, propyl, isopropyl, n-
- 11 - butyl, sec-butyl, tert-butyl, etc. The term "heteroalkyl" is intended to indicate an alkane group containing 1 or 2 heteroatoms selected from O, S or N. -
As used herein, the term "alkenyl" means a straight or branched-chain alkene group with 2-6 carbon atoms in the chain; the term "alkynyl" is intended to indicate a straight or branched-chain alkyne group with 2-6 carbon atoms in the chain.
As used herein, the terms "aryl" and "cycloalkyl" preferably refer to mono- and bicyclic ring structures comprising 5 to 12 carbon atoms, more preferably monocyclic rings comprising 5 to 6 carbon atoms. Where such rings comprise one or more heteroatoms, selected from N, S and O, (i.e., heterocyclic rings) such rings comprise a total of 5 to 12 atoms, more preferably 5 to 6 atoms. Heterocyclic rings include, but are not limited to, furyl, pyrrolyl, pyrazolyl, thienyl, imidazolyl, isoxazolyl, oxazolyl, thiazolyl, isothiazolyl, pyridyl, piperidinyl, piperazinyl, pyridazinyl, pyrimidinyl, pyrazinyl, morpholinyl, oxadiazolyl, thiadiazolyl, imidazolinyl, imidazolidinyl and the like. The ring may be substituted by one or more of the groups included in the definition of R2 above. It is understood that the substituents Cι-6 alkyl, Cι-6 alkenyl, Cι-6 alkynyl, Cι-6 alkoxy, Cι- heteroalkyl, Cι-6 aminoalkyl, Cι- haloalkyl or Cι-6 alkoxycarbonyl may, if present, be substituted by one or more of hydroxyl, C alkoxy, halogen, cyano, amino or nitro.
As used herein, the term "halogen" or "halo" includes chlorine, fluorine, iodine and bromine.
It is understood that the ring represented by the structure
Xf (X \
X^ .N
may be both saturated and unsaturated.
Compounds of the present invention may be prepared by methods analogous to the methods disclosed in GB 1,142,143 and US 3,816,433. Ways of modifying those methods to include other reagents etc. will be apparent to those skilled in the art.
Thus, for instance, compounds of formula I may be prepared as shown in the following reaction scheme.
- 12 - (Rι )tχ '(R2)n
^ H OHC (CH2)p Y ^
(X) (XI) [H]
(Rl )t^_χ ^=^(R2)n
*^ — (CH2)P — - y
(XX)
The starting compound having formula (X) may be prepared by general methods of organic synthesis. For general methods of preparing compounds of formula (X), reference is made to Fuller, R. W. et al., J. Med. Chem. 14:322-325 (1971); Foye, W. O., et al.. J. Pharm.Sci. 68:591-595 (1979); Bossier, J. R. et al.. Chem. Abstr. 66:46195h and 67:21527a (1967); Aldous, F. A. B., J. Med. Chem. 17:1100-1111 (1974); Fuller, R. W. et al., J. Pharm. Pharmacol. 25:828-829 (1973); Fuller, R. W. et al., Neuropharmacology 14:739-746 (1975); Conde, S. et al.. J. Med. Chem. 21 :978- 981 (1978); Lukovits, I. et al.. Int. J. Quantum Chem. 20:429-438 (1981); and Law, B., J. Cromatog. 407:1-18 (1987), the disclosures of which are incorporated by reference herein in their entirety. The radiolabelled derivatives having formula (XX) may be prepared by, for example, using a tritiated reducing agent to form the reductive amination or by utilizing a l4C-labelled starting material. Alternatively, where the starting compound comprises a carbonyl group, the compound having the formula (XXII) may be reduced with, for example, AIH3, diborane:methyl sulfide or other standard carbonyl reducing reagents to produce the ligand having the formula (XXX).
- 13 - (Ri * — 9 (R2)
* s333^i N- C- -(CH2)p-
Figure imgf000016_0001
(XXII)
i J (C H2)p Y L
(XXX)
The receptor ligands having formula (XXXII) may be prepared by nucleophilic displacement of an electrophile (E) by the amino derivative (XXXI). Examples of electrophiles which may be used for this purpose include halides such as I, Cl, Br, tosylate or mesylate.
(Rι)t (R2)
-(CH2)p-
Figure imgf000016_0002
(XXXI)
(Rι)t- (R2)n
)§1/N — (C H2)p Y —
Figure imgf000016_0003
(XXXII)
When Y in formula (XXXII) is -C(O)-, this compound may be prepared from oxidation of an sec. alcohol with for example pyridinium chlorocromate or N- chlorosuccimmide or CrO3-H2SO or nickel peroxide or metal (Al, K) or DCC- DMSO.
When Y in formula (XXXII) is -O-, this compound may be prepared by alkylation of an alcohol with arylhalides under for example Cu catalysis.
When Y in formula (XXXII) is -S-, this compound may be prepared by alkylation of a thiol with arylhalides under for example Cu catalysis.
- 14 . When Y in formula (XXXII) is -CHOH-, this compound may be prepared by reduction of the corresponding ketone by catalytic hydrogenation or by the use of NaBH or by the use of LiAlH .
Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts; and salts formed with suitable organic ligands. e.g. quarternary ammonium salts. Examples of pharmaceutically acceptable salts include the acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium, carbonate, chloride, clavulanate, citrate, dihydrochloride, fumarate, gluconate, glutamate, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate. lactate, lactobionate, laurate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, nitrate, N-methylglucamine ammonium salt, oleate, oxalate, phosphate/diphosphate, salicylate. stearate, sulfate, succinate. tannate, tartrate, tosylate, triethiodide and valerate salt.
The present invention includes within its scope prodrugs of the compounds of this invention. In general, such prodrugs are inactive derivatives of the compounds of this invention which are readily convertible in vivo into the required compound. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs," ed. H. Bundgaard, Elsevier, 1985. Metabolites of these compounds include active species produced upon introduction of compounds of this invention into the biological milieu.
Where the compounds according to the invention have at least one chiral center, they may exist as a racemate or as enantiomers. It should be noted that all such isomers and mixtures thereof are included in the scope of the present invention. Furthermore, some of the crystalline forms for compounds of the present invention may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds of the present invention may form
- 15 - solvates with water (i.e., hydrates) or common organic solvents. Such solvates are also included in the scope of this invention.
Where the processes for the preparation of the compounds according to the invention give rise to mixtures of stereoisomers, such isomers may be separated by conventional techniques such as preparative chiral chromatography. The compounds may be prepared in racemic form, or individual enantiomers may be prepared either by stereoselective synthesis or by resolution. The compounds may, for example, be resolved into their component enantiomers by standard techniques, such as the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-p-toluoyl-d-tartaric acid and/or (+)-di-p-toluoyl-l-tartaric acid followed by fractional crystallization and regeneration of the free base. The compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary.
During any of the processes for preparation of the compounds of the present invention, it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.
Compounds of the present invention may be administered in any of the foregoing compositions and according to dosage regimens established in the art whenever specific pharmacological modification of the activity of muscarinic receptors is required.
The present invention also provides pharmaceutical compositions comprising one or more compounds of the invention together with a pharmaceutically acceptable diluent or excipient. Preferably such compositions are in unit dosage forms such as tablets, pills, capsules (including sustained-release or delayed-release formulations), powders, granules, elixirs, tinctures, syrups and emulsions, sterile parenteral solutions or suspensions, aerosol or liquid sprays, drops, ampoules, auto-injector devices or suppositories; for oral, parenteral (e.g. intravenous, intramuscular or subcutaneous), intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation, and may be formulated in an appropriate manner and in accordance with
- 16 - accepted practices such as those disclosed in Remington 's Pharmaceutical Sciences, Gennaro, Ed., Mack Publishing Co.. Easton PA, 1990. Alternatively, .the compositions may be in sustained-release form suitable for once-weekly or once-monthly administration; for example, an insoluble salt of the active compound, such as the decanoate salt, may be adapted to provide a depot preparation for intramuscular injection. The present invention also contemplates providing suitable topical formulations for administration to. e.g. eye or skin or mucosa.
For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents, flavoring agents and coloring agents can also be incorporated into the mixture. Suitable binders include, without limitation, starch, gelatin, natural sugars such as glucose or beta-lactose, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like. Lubricants used in these dosage forms include, without limitation, sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like. For preparing solid compositions such as tablets, the active ingredient is mixed with a suitable pharmaceutical excipient, e.g. such as the ones described above, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a pharmaceutically acceptable salt thereof. By the term "homogeneous" is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. The solid preformulation composition may then be subdivided into unit dosage forms of the type described above containing from 0.1 to about 50 mg of the active ingredient of the present invention. The tablets or pills of the present composition may be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner core containing the active compound and an outer layer as a coating surrounding the core. The outer coating may be an enteric layer which serves to resist disintegration in the stomach and permits the inner core to pass intact into the
- 17 - duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with conventional materials such as shellac, cetyl alcohol and cellulose acetate. The liquid forms in which the present compositions may be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical carriers. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate. dextran, sodium carboxymethylcellulose, gelatin. methylcellulose or polyvinyl-pyrrolidone. Other dispersing agents which may be employed include glycerin and the like. For parenteral administration, sterile suspensions and solutions are desired. Isotonic preparations which generally contain suitable preservatives are employed when intravenous administration is desired. The compositions can also be formulated as an ophthalmic solution or suspension formation, i.e., eye drops, for ocular administration
Consequently, the present invention also relates to a method of alleviating or treating a disease or condition in which modification of muscarinic receptor activity, in particular ml receptor activity, has a beneficial effect by administering a therapeutically effective amount of a compound of the present invention to a subject in need of such treatment. Such diseases or conditions may, for instance arise from inadequate stimulation or activation of muscarinic receptors. It is anticipated that by using compounds which are selective for a particular muscarinic receptor subtype, in particular ml, the problems with adverse side effects observed with the known muscarinic drugs, such as tachycardia or bradycardia or gastrointestinal effects, may substantially be avoided.
The term "subject," as used herein refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment. The term "therapeutically effective amount" as used herein means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease being treated.
- 18 - Preferably, compounds of general formula I exhibit subtype selectivity for the muscarinic ml receptor subtype. Likewise, the compounds exhibit selectivity for the muscarinic ml receptor subtype compared to other human G-protein coupled receptors tested including serotonin, histamine, dopamine or adrenergic receptors. One important implication of this selectivity is that these compounds may be effective in the treatment or amelioration of a number of diseases and disorders of the central nervous system without the undesirable side effects previously observed with non- selective compounds.
The ability of the compounds of the present invention to demonstrate muscarinic ml receptor subtype selectivity makes them potentially very useful in treating a number of diseases and disorders characterized by cognitive impairment such as attention deficit disorder, or neurodegenerative diseases, e.g. Alzheimer's disease, other forms of age-related cognitive decline, e.g. senile dementia, or dementia-related symptoms such as decreased motor activity, mood changes, anergia, apathy, restlessness and aggressive behavior. It is currently believed that the muscarinic ml receptor may also be involved in control of intraocular pressure, and that muscarinic ml agonists may therefore be used to treat or alleviate ocular diseases such as glaucoma.
Advantageously, compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses two, three or four times daily. Furthermore, compounds for the present invention may be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to persons skilled in the art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.
The dosage regimen utilizing the compounds of the present invention is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound employed. A physician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the disease or disorder which is being treated.
- 19 - The daily dosage of the products may be varied over a wide range from 0.01 to 100 mg per adult human per day. For oral administration, the compositions are preferably provided in the form of tablets containing 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0 or 50.0 mg of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. A unit dose typically contains from about 0.001 mg to about 50 mg of the active ingredient, preferably from about 1 mg to about 10 mg of active ingredient. An effective amount of the drug is ordinarily supplied at a dosage level of from about 0.0001 mg/kg to about 25 mg/kg of body weight per day. Preferably, the range is from about 0.001 to 10 mg/kg of body weight per day, and especially from about 0.001 mg/kg to 1 mg/kg of body weight per day. The compounds may be administered on a regimen of 1 to 4 times per day.
Compounds according to the present invention may be used alone at appropriate dosages defined by routine testing in order to obtain optimal pharmacological effect on a muscarinic receptor, in particular the muscarinic ml receptor subtype, while minimizing any potential toxic or otherwise unwanted effects. In addition, co-administration or sequential administration of other agents which improve the effect of the compound may, in some cases, be desirable.
The pharmacological properties and the selectivity of the compounds of this invention for specific muscarinic receptor subtypes may be demonstrated by a number of different assay methods using recombinant receptor subtypes, preferably of the human receptors if these are available, e.g. conventional second messenger or binding assays. A particularly convenient functional assay system is the receptor selection and amplification assay disclosed in US 5,707,798 describing a method of screening for bioactive compounds by utilizing the ability of cells transfected with receptor DNA, e.g. coding for the different muscarinic subtypes, to amplify in the presence of a ligand of the receptor. Cell amplification is detected as increased levels of a marker also expressed by the cells.
The invention is disclosed in further detail in the following examples which are not in any way intended to limit the scope of the invention as claimed.
- 20 - Examples
Example I - 4-n-Butyl-l-[4-(2-methylphenyl)-4-oxo-l-butyl]piperidine (5) l-Benzyl-4-n-butylidenepiperidine (2). A 500 mL 3-necked flask fitted with a stirrer, was charged with sodium hydride (1.61 g, 67 mmol) and DMSO (40 mL). The resulting suspension was heated to 90°C for 30 min, until the evolution of hydrogen ceased. The suspension was cooled on an ice-bath for 20 min followed by addition of a slurry of butyltriphenylphosphonium bromide (26.6 g, 67 mmol) in DMSO (70 mL). The red mixture was stirred for 15 min at rt. l-Benzyl-4-piperidone 1 (14.0 g, 74 mmol) was slowly added over 30 min. and the mixture was stirred at room temperature over night. H2O (200 mL) was added to the reaction mixture followed by extraction with heptane (4 x 100 mL) and ethyl acetate (2 x 100 mL). The combined organic phases were dried and evaporated to dryness, producing 38.1 g of a yellow oil. The oil was distilled to give 14.9 g (88 %) of 2, bp 101-105°C (0.1 mm Hg). Η NMR (CDC13) 0.90-0.95 (t, 3H), 1.25-1.41 (m, 2H), 1.90-2.20 (m, 2H), 2.18-2.30 (m, 4H), 2.40-2.45 (m, 4H), 2.50 (s, 2H), 5.17 (t, 1H), 7.20-7.42 (m, 5H).
4-n-Butylpiperidine (3). In a 500 mL flask fitted with a stirrer was added a slurry of 2 (13.2 g, 58 mmol) and 10% palladium on charcoal (1.2 g) in ethanol (70 mL), followed by addition of concentrated hydrochloric acid (1.5 mL). The reaction flask was evacuated and hydrogen was added via a reaction flask. A total of 2.5 dm3 of hydrogen was consumed. The reaction mixture was filtered and evaporated and the residue was dissolved in H2O (40 mL) and NaOH (20 mL, 2 M) followed by extraction with ethyl acetate (3 x 100 mL). The combined organic phases were washed with brine (30 mL) and evaporated to dryness to produce 7.1 g of crude 3. The crude product was subjected to CC [eluent: heptane : EtOAc (4:1)] to give pure 3 (2.7 g, 33%). Η NMR (CDC13) 0.85 (t, 3H). 1.0-1.38 (m, 9H), 1.65 (dd, 2H). 2.38 (s. 1H), 2.55 (dt, 2H), 3.04 (dt, 2H). 4-(4-n-Butylpiperidin-l-yl)butanenitrile (4). In a 100 mL flask with a magnetic stirrer was placed 3 (2.3 g, 16.4 mmol), 4-bromobutyronitrile (2.4 g, 16.4 mmol), potassium carbonate powder (2.5 g, 18 mmol) in acetonitrile (20 mL). The reaction mixture was stirred at rt for 5 h followed by addition of H 0 (15 mL). The mixture was extracted with ethyl acetate (3 x 30 mL) and the combined organic phases were
- 21 - evaporated to dryness to produce 3.9 of crude 4. The crude product was subjected to CC [eluent: heptane : EtOAc (1 : 1)] to give pure 4 (2.3 g, 87%). 'H NMR (CDC13) 0.82 (t, 3H), 1.19-1.37 (m, 9H), 1.64-1.75 (d, 2H), 1.84-2.01 (m, 4H), 2.39-2.54 (m, 4H), 2.89-2.97 (d, 2H). 4-n-Butyl-l-[4-(2-methylphenyl)-4-oxo-l -butyljpiperidine (5). In a 25 mL oven- dried flask was charged Mg turnings (125 mg, 5.2 mmol) which were activated by the use of a heat-gun. Under inert atmosphere was added a suspension of 2-iodoanisole (1.13 g, 5.2 mmol) in Et2O (4 mL) and the reaction mixture was allowed to stand at rt for 1 hour. Compound 4 (720 mg, 3.4 mmol) dissolved in Et O (4 mL) was added and the mixture was refluxed over-night. THF (15 mL) and sulfuric acid (4 mL, 2 M) was added and the reaction mixture was stirred for 4 h, followed by addition of NaOH (6 mL, 2 M). The reaction mixture was extracted with ethyl acetate (3 x 50 mL), and the combined organic phases were evaporated to dryness to produce 1.2 g of crude 5. The crude product was subjected to CC [eluent: CH Cl2:CH3OH (99:1)] to give pure 5 (0.42 g, 26%). Η NMR (CDCI3) 0.83 (t, 3H), 1.20-1.42 (m, 9H), 1.65-1.73 (d, 2H), 1.96-2.20 (m, 4H), 2.53 (t, 2H), 3.02-3.17 (m, 4H), 3.89 (s, 3H), 6.95-7.01 (m, 2H), 7.44 (t, 1H), 7.65 (d, 1H).
Example II - 3-Hydroxymethyl-[4-(2-methylphenyl)-4-oxo-l-butyl]piperidine (7) 4-(3-Hydroxymethyl-piperidin-l-yl)-butyronitrile (6). In an oven-dried 25 mL flask was placed piperidine-3-yl-methanol (1.12 g, 10 mmol) in acetonitrile (10 mL), followed by addition of potassium carbonate (1.38 g, 10 mmol) and 4- bromobutyronitrile (0.90 mL, 9 mmol). The reaction mixture was stirred at rt. for 12 h. The mixture was filtered and evaporated to dryness. Addition of H O (20 mL) was followed by extraction with ethyl acetate (3 x 20 mL) and the combined organic phases were dried (MgS0 ) and evaporated to dryness to produce 1.50 g of crude 6 which was used without further purification in the synthesis of compound 7.
3-Hydroxymethyl-[4-(2-methylphenyl)-4-oxo-l-butyl]piperidine (7). In a 50 mL oven-dried flask was added Mg turnings (780 mg, 32 mmol), which were activated by the use of a heat-gun under vacuum, followed by addition of anhydrous THF (7 mL). Under inert atmosphere was added a suspension of 2-iodotoluene (5.3 g, 24 mmol) in THF (10 mL) and the reaction mixture was allowed to reflux for 4 hours. A suspension of compound 6 (1.50 g, 8 mmol) in THF (5 mL) was added via a syringe followed by addition of CuBr (23 mg, 0.16 mmol, 2 mol %) and the reaction mixture
- 22 - was stirred at rt overnight. The reaction mixture was quenched by addition of H2SO (20 mL, 2 M) and stirred at rt for 2 hours followed by addition of NaQH (8 mL, 2 M). Addition of THF (15 mL) was followed by extraction with CH2C12 (3 x 20 mL), and the organic phases were dried (MgSO ) and evaporated to dryness to produce 0.41 g of crude 7. The crude product was subjected to preparative HPLC CC [eluent: Buffer A: 0.1% TFA; Buffer B: 80% CH3CN + 0.1%TFAj to produce an analytical pure sample of compound 7. LC-MS [M+ Hj+ 275 (cald. 275.2).
Example III - 2-Propyl-[4-(2-methylphenyl)-4-oxo-l -butyljpiperidine (9) 4-(2-propyl-pipeήdin-l-yl)-butyronitrile (8). A mixture of 2-propylpiperidine
(550 mg, 4.3 mmol), 4-bromobutyronitrile (430 mg, 3.0 mmol) and potassium carbonate (550 mg, 4.0 mmol) in acetonitrile (5 mL) was stirred at rt for 12 h., followed by addition of a saturated brine (25 mL). The reaction mixture was extracted with ethyl acetate (3 x 25 mL) and the combined organic phases were dried (MgSO ) and evaporated to dryness to produce crude 8. The crude product was subjected to CC [eluent: CH2C12 : MeOH (99:1)] to give pure 8 (0.48 g, 83 %); LC- MS [M+ H]+ 194 (cald. 194.2).
2-Propyl-[4-(2-methylphenyl)-4-oxo-l -butyljpiperidine (9). In a 10 mL oven- dried flask was added Mg turnings (97 mg, 4.1 mmol) which were activated by the use of a heat-gun under vacuum. Under inert atmosphere was added a suspension of 2-iodotoluene (380 1, 2.8 mmol) in Et2O (3 mL) and the reaction mixture was allowed to reflux for 1 hour. A mixture of compound 8 (0.43 g, 2.2 mmol) in CH C1 (3 mL) was added via a syringe and the reaction mixture was stirred at rt overnight. The reaction mixture was quenched by addition of H2SO (10 mL, 2 M) and stirred at rt for 12 hours followed by addition of NaOH (10 mL, 2 M). Addition of THF (15 mL) was followed by extraction with ethyl acetate (3 x 50 mL) and the combined organic phases are washed with brine (10 mL) and NaOH (10 mL, 2 M), dried (MgS04) and evaporated to dryness to produce 0.43 g of crude 9. The crude product was subjected to preparative HPLC [eluent: Buffer A: 0.1% TFA; Buffer B: 80% CH3CN + 0.1%TFAj to produce an analytically pure sample of compound 9; LC-MS [ + H]+ 287 (cald. 287.2).
- 23 - Example IV - l-[4-(2-methylphenyl)-4-oxo-l-butyl]piperidine (11)
In a 10 mL oven-dried flask was added Mg turnings (97 mg, 4.1 mmol) which was activated by the use of a heat-gun under vacuum. Under inert atmosphere was added a suspension of 2-iodo-toluene (380 L , 3.0 mmol) in Et20 (3 mL) and the reaction mixture was allowed to reflux for 1 hours. A suspension of 4-piperidin-l-yl- butanenitrile 10 (Dahlbom et. al. Acta. Chem. Scand. 1951, 5, 690-697) (0.305 mg, 2.0 mmol) in CH2C12 (3 mL) was added via a syringe and the reaction mixture was stirred at rt overnight. The reaction mixture was quenched by addition of H2S0 (10 mL, 2 M) and stirred at rt for 12 hours followed by addition of NaOH (12 mL, 2 M). Addition of THF (15 mL) was followed by extraction with ethyl acetate (3 x 50 mL), and the combined organic phases are washed with brine (10 mL) and NaOH (10 mL, 2 M), and dried (MgS0 ) and evaporated to dryness to produce 0.21 g of crude 11. The crude product was subjected to preparative HPLC [eluent: Buffer A: 0.1% TFA; Buffer B: 80% CH3CN + 0.1%TFA] to produce an analytically pure sample of compound 11; LC-MS [M+ Hj+ 245 (cald. 245.2).
Example V - 4-methyl-l-[4-(4-bromophenyl)-4-oxo-l-butyl]piperidine (12)
In a 10 mL dried flask was added 4-methylpiperidine (719 L, 6 mmol), dioxane (5 mL) followed by addition of potassium carbonate (0.30 g, 2.18 mmol), potassium iodide (10 mg) and 4-bromo-4-chlorobutyrophenone (785 mg, 2.76 mmol). The reaction mixture was left at 110°C for 12 h., followed by dilution with H20 (10 mL). The reaction mixture was extracted with Et20 (3 x 15 mL) and the combined organic phases are dried (MgS04) and evaporated to dryness to produce 0.50 g of crude 12. The crude product was subjected to preparative HPLC [eluent: Buffer A: 0.1% TFA; Buffer B: 80% CH3CN + 0.1%TFA] to produce an analytical pure sample of compound 12; LC-MS [M+ H]+ 322 (cald. 323.1).
Example VI - l-[4-(2-methylphenyl)4-oxo-l-butyl]pyrrolidine (13)
In a 10 mL oven-dried flask was charged Mg turnings (30 mg, 1.2 mmol) which were activated under vacuum by the use of a heat-gun. Under inert atmosphere was added a solution of 2-iodotoluene (0.22 g, 1.0 mmol) in Et20 (2 mL) and the reaction mixture was allowed to reflux for 1 hour. A mixture of 4-pyrrolidin-l-yl-butyronitrile (Burckhalter et. al. J Org. Chem. 1961, 26, 4070-4076) (0.14 g, 1.0 mmol) in CH2C12 (2 mL) was added via a syringe and the reaction mixture was stirred at rt overnight.
- 24 - The reaction mixture was quenched by addition of H2S04 (10 mL. 2 M) and stirred at rt for 2 hours followed by addition of NaOH (10 mL, 2 M). Addition-of THF (15 mL) was followed by extraction with ethyl acetate (3 x 20 mL), and the organic phases were dried (MgS04) and evaporated to dryness to produce 0.12 g of crude 13. The crude product was subjected to preparative HPLC [eluent: Buffer A: 0.1% TFA; Buffer B: 80% CH3CN + 0.1%TFA] to produce an analytical pure sample of compound 13. LC-MS [M+ H]+ 231 (cald. 231.3).
Example VII - 4-Methyl-l-[4-(2-methylphenyl)4-oxo-l-butyl]piperazine (15) 4-(4-Methyl-piperazin-l-yl)-butyronitrile (14). In a 25 mL flask was placed 1- methyl-piperazine (0.52 g, 5.1 mmol), 4-bromobutyronitrile (0.78 g, 5.3 mmol) and potassium carbonate (0.71 g, 5.3 mmol) suspended in acetonitrile (5 mL). The reaction mixture was stirred at rt for 4 h., followed by addition of H20 (20 mL) and extraction with ethyl acetate (3 x 25 mL). The combined organic phases were washed with brine (25 mL), dried (MgS0 ) and evaporated to dryness to produce 0.72 g of crude 14 which was used without further purification in the synthesis of compound 15.
4-Methyl-l -[4-(2-methylphenyl)4-oxo-l -butyljpiperazine (15). In a 10 mL oven- dried flask was added Mg turnings (116 mg, 4.0 mmol) which were activated under vacuum by the use of a heat-gun. Under inert atmosphere was added a mixture of 2- iodotoluene (0.65 g, 3.0 mmol) in Et20 (3 mL) and the reaction mixture was allowed to reflux for 1 hour. A solution of compound 14 (0.33 g, 2.0 mmol) in CH C1 (3 mL) was added via a syringe and the reaction mixture was stirred at rt overnight. The reaction mixture was quenched by addition of H2S04 (6 mL, 2 M) and stirred at rt for 2 hours followed by addition of NaOH (8 mL, 2 M). Addition of THF (15 mL) was followed by extraction with CH2C12 (3 x 20 mL). The organic phases were dried (MgS0 ) and evaporated to dryness to produce 0.26 g of crude 15. The crude product was subjected to preparative HPLC [eluent: Buffer A: 0.1% TFA; Buffer B: 80% CH3CN + 0.1%TFAj to produce an analytically pure sample of compound 15. LC-MS [ + Hj+ 260 (cald. 260.4).
- 25 - Example VIII - 4-n-Butyl-l-[4-(2-methylphenyl)4-oxo-l -butyljpiperazine (17)
4-(4-Butyl-piperazin-l-yl)-butyronitrile (16). In a 25 mL flask was placed 1-butyl- piperazine (712 mg, 5.0 mmol), 4-bromobutyronitrile (779 mg, 5.3 mmol) and potassium carbonate (687 mg, 5.0 mmol) suspended in acetonitrile (5 mL). The reaction mixture was stirred at rt for 12 h., followed by addition of H20 (20 mL) and extraction with ethyl acetate (3 x 25 mL). The combined organic phases were washed with brine (25 mL), dried (MgS0 ) and evaporated to dryness to produce 0.89 g of crude 16 which was used without further purification in the synthesis of compound 17. 4-n-Butyl-l-[4-(2-methylphenyl)4-oxo-l -butyljpiperazine (17). In a 10 mL oven- dried flask charged with Mg turnings (100 mg, 4.0 mmol) which was activated under vacuum by the use of a heat-gun. Under inert atmosphere was added a suspension of 2-iodotoluene (0.66 g, 3.0 mmol) in Et20 (3 mL) and the reaction mixture was allowed to reflux for 1 hours. A suspension of compound 16 (0.43 g, 2.0 mmol) in CH2C12 (3 mL) was added via a syringe and the reaction mixture was stirred at rt overnight. The reaction mixture was quenched by addition of H2S0 (6 mL, 2 M) and stirred at rt for 2 hours followed by addition of NaOH (8 mL, 2 M). Addition of THF (15 mL) was followed by extraction with CH2C12 (3 x 20 mL), and the organic phases were dried (MgS04) and evaporated to dryness to produce 0.50 g of crude 17. The crude product was subjected to preparative HPLC [eluent: Buffer A: 0.1% TFA; Buffer B: 80% CH3CN + 0.1%TFA] to produce an analytical pure sample of compound 17. LC-MS [M+ H]+ 302 (cald. 302.5).
Example IX - 4-n-Butyl-l-[4-(2-ethoxyphenyl)-4-oxo-l-butylJpiperidine (18) In a 10 mL oven-dried flask was added Mg turnings (94 mg, 3.8 mmol) which was activated by the use of a heat-gun under vacuum. Under inert atmosphere was added a suspension of l-ethoxy-2-iodobenzene (0.71 g, 2.9 mmol) in Et20 (3 mL) and the reaction mixture was allowed to reflux for 3 hours. Compound 4 (0.40 g, 1.9 mmol) dissolved in CH2C12 (3 mL) was added and the mixture was stirred at 40°C for additional 3 hours. The reaction mixture was quenched by addition of H2S04 (10 mL, 2 M) and left stirring overnight at room temperature, followed by addition of NaOH (20 mL, 2 M) until basic conditions. The reaction mixture was extrated with ethyl acetate (3 x 50 mL) ) and the combined organic phases are washed with brine (10 mL) and NaOH (10 mL, 2 M), and the combined organic phases were dried (MgS04) and
- 26 - evaporated to dryness to produce 0.60 g of crude 18. The crude product was subjected to CC [eluent: Tol : EtOAc (1 :1)] to give pure 18 (0.32 g, 34 %); LC-MS [M + H]+ 331 (cald. 331.5).
Example X - 4-n-Butyl-l-[4-(2,3-dimethylphenyl)-4-oxo-l-butyl]piperidine (19)
In a 10 mL oven-dried flask was added Mg turnings (94 mg, 3.8 mmol) which was activated under vacuum by the use of a heat-gun. Under inert atmosphere was added a suspension of l-iodo-2,3-dimethylbenzene (0.69 g, 3.0 mmol) in Et20 (5 mL) under spontaneously reflux, and the reaction mixture was allowed to reflux for 4 hours. A suspension of compound 4 (0.41 g, 2.0 mmol) in CH2C12 (2 mL) was added to the reaction mixture and left at rt overnight. The reaction mixture was quenched by addition of H2S0 (7 mL, 2 M) and stirred at rt for 3 hours, followed by addition of NaOH (20 mL, 2 M) until basic conditions. The reaction mixture was extracted with ethyl acetate (3 x 50 mL) and the combined organic phases are washed with brine (10 mL) and NaOH (10 mL, 2 M), and the organic phases were dried (MgS04) and evaporated to dryness to produce 0.69 g of crude 19. The crude product was subjected to CC [eluent: CH2C12 : MeOH (99:1)] to give pure 19 (0.40 g, 64 %); LC-MS [M + H]+ 315 (cald. 315.5).
Example XI - 4-n-Butyl-l-[4-(2,4-dimethylphenyl)-4-oxo-l-butyl]piperidine (20)
In a 10 mL oven-dried flask charged with Mg turnings (95 mg, 3.9 mmol) which was activated under vacuum by the use of a heat-gun. Under inert atmosphere was added a suspension of l-iodo-2,4-dimethylbenzene (0.69 g, 2.9 mmol) in Et20 (4.5 mL) under spontaneously reflux, and the reaction mixture was allowed to reflux for 3 hours. Compound 4 (0.41 g, 2.0 mmol) dissolved in CH2C12 (2 mL) was added under inert atmosphere to the reaction mixture and left stirring at rt overnight. The reaction mixture was quenched by addition of H2S0 (8 mL, 2 M) and stirred at rt for 4 hours, then the reaction mixture was basified by addition of NaOH (20 mL, 2 M). Addition of THF (20 mL) was followed by extraction with ethyl acetate (3 x 50 mL) and the combined organic phases are washed with brine (10 mL) and NaOH (10 mL, 2 M), and the organic phases were dried (MgS0 ) and evaporated to dryness to produce 0.61 g of crude 20. The crude product was subjected to CC [eluent: CH2C12 : MeOH (99:1)] to give pure 20 (0.21 g, 35 %); LC-MS [M+ Hf 315 (cald. 315.5).
- 27 - Example XII - 4-n-Butyl-l-[4-(2-methoxyphenyl)-4-oxo-l -butyljpiperidine (21).
In a 10 mL oven-dried flask charged with Mg turnings (0.12 g, 4.9 mmol) which was activated under vacuum by the use of a heat-gun. Under inert atmosphere was added a suspension of l-bromo-2-ethylbenzene (0.66 g, 3.6 mmol) in Et20 (2 mL) and the reaction mixture was allowed to reflux for 2 hours. A suspension of compound 4 (0.50 g, 2.4 mmol) in CH2C1 (2 mL) was added via a syringe and the reaction mixture was stirred at rt overnight. The reaction mixture was quenched by addition of H2S0 (14 mL, 2 M) and stirred at rt for 2 hours followed by addition of NaOH (20 mL, 2 M). Addition of THF (20 mL) was followed by extraction with ethyl acetate (3 x 50 mL) and the combined organic phases are washed with brine (10 mL) and NaOH (10 mL, 2 M), and the organic phases were dried (MgS0 ) and evaporated to dryness to produce 0.75 g of crude 21. The crude product was subjected to CC [eluent: CH2C12 : MeOH (99:1)] to give pure 21 (0.68 g, 90 %); LC-MS [M + Hj+ 315 (cald. 315.5).
Example XIII - 4-n-Butyl-l-[4-(2,4-dimethylphenyl)-4-oxo-l-butylJpiperidine (22)
A 10 mL oven-dried flask was charged with Mg turnings (88 mg, 3.6 mmol) andweactivated under vacuum by the use of a heat-gun. Under inert atmosphere was added a suspension of 1 -Iodo-2-methoxymethylbenzene (0.67 g, 2.7 mmol) in Et 0 (4 mL) and the reaction mixture was allowed to reflux for 1 hours. A suspension of compound 8 (0.38 g, 1.8 mmol) in CH2C12 (4 mL) was added via a syringe and the reaction mixture was stirred at rt overnight. The reaction mixture was quenched by addition of H2S0 (10 mL, 2 M) and stirred at rt for 2 hours followed by addition of NaOH (10 mL, 2 M). Addition of THF (15 mL) was followed by extraction with ethyl acetate (3 x 50 mL) and the combined organic phases are washed with brine (10 mL) and NaOH (10 mL, 2 M), and the organic phases were dried (MgS04) and evaporated to dryness to produce 0.51 g of crude 22. The crude product was subjected to CC [eluent: CH2C12 : MeOH (99:1)] to give pure 22 (0.14 g, 23 %); LC-MS [M + Hj+ 331 (cald. 331.5).
Example XIV - 4-n-Butyl-l-[4-(2-pyridinyl)-4-oxo-l-butyl]piperidine (24)
4-(4-Butyl-piperidin-l-yl)butyric acid methyl ester (23). To a 25 mL reaction flask was added 4-bromo-butyric acid methyl ester (2.04 g, 11.2 mmol), compound 3 (1.51 g, 10.8 mmol) and potassium carbonate (1.63 g, 11.8 mmol) suspended in
- 28 - CH3CN (10 mL). The reaction mixture was stirred over-night at rt followed by filtration and evaporation to dryness. Addition of H20 (50 mL) was followed by extraction with ethyl acetate (3 x 100 mL). The combined organic phases were dried (MgS0 ) and evaporated to dryness, to produce 2.84 g of crude 23. The crude product was subjected to CC [eluent: CH2C12 : MeOH (99:1)] to give pure 23 (1.93 g, 75%). LC-MS [M+ H]+ 241 (cald. 241.2).
4-n-Butyl-l-[4-(2-pyridinyl)-4-oxo-l -butyljpiperidine (24). To a dry 25 mL reaction flask was added 2-bromopyridine (200 mg, 1.3 mmol) dissolved in CH2C12 (3 mL) and the temperature was adjusted to -78°C. After being stirred for 20 min, addition of n-BuLi (0.84 mL, 1.4 mmol) was conducted under inert atmosphere. After additional 30 min, a solution of 23 dissolved in CH2C1 (2 mL) was added. The reaction mixture was left to warm to rt over-night before being quenched with H2S0 (5 mL, 1 M). The reaction mixture was extracted with ethyl acetate (6 x 25 mL) and the combined organic phases were dried (MgS04) and evaporated to dryness, to produce 0.31 g of crude 24. The crude product was subjected to CC [eluent: CH2C12 : MeOH (10:1)] to give pure 24 (75 mg, 12%). LC-MS [M+ H]+ 288 (cald. 288.2).
Example XV - 4-n-Butyl-l-[4-(2-hydroxyphenyl)-4-oxo-l-butyl]piperidine (27) l-Benzyloxy-2-iodo-benzene (25). In a 25 mL ovendried flask 2-iodophenol (1.03 g, 4.7 mmol) and potassium carbonate (0.71 g, 5.2 mmol) were dissolved in dry acetone (10 mL). The mixture was stirred for 15 min followed by addition of benzylbromide (0.61 mL, 5.2 mmol) and left over-night at rt. Addition of H20 (50 mL) followed by extraction with ethyl acetate (3 x 50 mL) and the combined organic phases were dried (MgS04) and evaporated to dryness, to produce 1.7 g of crude 25. The crude product was subjected to CC [eluent: Heptane : EtOAc (9: 1)] to give pure 25 (1.2 g, 81%). LC-MS [ + H]+ 310 (cald. 310.0).
4-n-Butyl-l -[4-(2-benzyloxyphenyl)-4-oxo-l -butyljpiperidine (26). In a 25 mL oven-dried flask was added Mg turnings (123 mg, 5.1 mmol) which was activated by the use of a heat-gun under vacuum. Under inert atmosphere was added a solution of l-benzyloxy-2-iodo-benzene (25) (1.18 g, 3.8 mmol) in Et20 (10 mL) and the reaction mixture was allowed to reflux for 3.5 hours. A solution of 4-(4-n- butylpiperidin-l-yl)butanenitrile 4 (0.53 g, 2.5 mmol) dissolved in CH2C12 (3 mL) was added and the reaction mixture and was stirred at 40°C over-night. The reaction mixture was quenched by addition of H S04 (10 mL, 2 M) and left stirring for 1 hour,
- 29 - followed by addition of NaOH (20 mL, 2 M) until basic conditions. The reaction mixture was extrated with ethyl acetate (3 x 50 mL) ) and the combined organic phases are washed with brine (10 mL) and NaOH (10 mL, 2 M), and the combined organic phases were dried (MgS0 ) and evaporated to dryness to produce 1.28 g of crude 26. The crude product was subjected to CC [eluent: Tol : EtOAc (1 : 1)] to give pure 26 (0.51 g, 51 %); LC-MS [M+ H]+ 393 (cald. 393.7).
4-n-Butyl-l-[4-(2-hydroxyphenyl)-4-oxo-l -butyljpiperidine (27). To a 25 mL reaction flask was added a solution of 4-n-Butyl-l-[4-(2-benzyloxyphenyl)-4-oxo-l- butyljpiperidine (26) (49 mg, 1.2 mmol) dissolved in dry EtOH (10 mL) and cone. HCl (0.1 mL) followed by addition of palladium on charcoal (40 mg). The reaction flask was then charged with H2 by the use of balloon technique and left stirring at rt over-night under H2 atmosphere. The reaction mixture was basified by addition of NaOH (2 mL, 2.0 M) and filtered through celite. The aqueous phase was extracted with ethyl acetate (3 x 50 mL) and the combined organic phases were washed with brine (10 mL) and NaOH (10 mL, 2 M), dried (MgS04) and evaporated to dryness to produce 0.42 g of crude 27. The crude product was subjected to CC [eluent: : CH2C12 : MeOH (99:1)] to give pure 27 (0.21 g, 58 %); LC-MS [M+ H]+ 303 (cald. 303.2).
Example XVI - Screening of test compounds in an assay using muscarinic receptor subtypes ml, m2, m3, m4 and m5
Transfection of cells with muscarinic receptor DNAs (general procedure) NIH 3T3 cells (available from the American Type Culture Collection as ATCC CRL 1658) were grown at 37°C in a humidified atmosphere (5% C02) incubator in Dulbecco's modified Eagle's medium (DMEM) supplemented with 4.5 g/1 glucose, 4 mM glutamine, 50 units/ml penicillin, 50 units/ml streptomycin (available from Advanced Biotechnologies, Inc., Gaithersburg, MD) and 10% calf serum (available from Sigma, St. Louis, MI). The cells were treated with trypsin-EDTA, spun down and plated at 2xl06 per 15 cm dish in 20 ml of DMEM containing 10% calf serum.
The ml-m5 muscarinic receptor subtypes were cloned substantially as described by Bonner et al., Science 237, 1987, p. 527, and Bonner et al., Neuron 1, 1988, p. 403. For the m2 and m4 receptors, the cells were co-transfected with DNA encoding a chimera between the Gq protein and the five carboxy-terminal amino acids of the Gi protein (the Gq-i5 construct is described by Conklin et al., Nature 363, 1993, p.274).
- 30 - On day one, the cells were transfected using the Superfect transfection reagent (available from Qiagen, Valencia, CA) in accordance with the manufacturer's instructions. Receptor DNA, β-gal DNA (pSI-β-galactosidase available from Promega, Madison , WI), chimeric Gq-i5 DNA for the m2 and m4 receptor subtype assays, and salmon sperm DNA (available from Sigma, St. Louis, MI) as filler to a total of 20 μg DNA was added per plate. Prior to addition to the plates, 60 μl Superfect was added to the DNA and mixed thoroughly by pipetting up and down several times. The mixture was incubated at room temperature for 10-15 minutes. The media were aspirated, and 12 ml fresh DMEM containing 10% calf serum and 50 units/ml penicillin/streptomycin was added to the plates. The DNA-Superfect solution was mixed once more with a pipette and added to the plate which was swirled to distribute the DNA mixture evenly over the surface. The cells were incubated overnight at 37°C and 5% C02.
After incubation, the media were aspirated and the plates were rinsed once with a 15 ml volume of Hank's Buffered Saline. The plates were swirled to ensure thorough rinsing. 20 ml fresh DMEM supplemented with 10% calf serum and 50 units/ml penicillin/streptomycin was added to the plates. The cells were incubated for 24-48 hours until the plates were 100% confluent.
Assay of NIH 3T3 cells transfected with muscarinic receptor subtypes (seneral procedure) DMEM containing 2% Cyto-SF3 was heated at 37°C in a water bath under sterile conditions. Sterile working stock solutions of test compounds to be assayed were prepared by diluting the compounds in DMEM to 8x the final concentration for testing. The compound (carbachol) to be included in the assay as a positive control was also diluted in DMEM to 8x the final concentration. 50 μl of the DMEM containing 2% Cyto-SF3 was added to each well of 96-well microtiter plates under sterile conditions. Then, 16 μl of compound solutions were added to the top wells of the plates, and dilution of the solutions was performed by taking 16 μl of the compound solutions from the top wells and pipetting them into the next row of wells. This procedure was repeated with each subsequent row of wells, except that 50 μl medium alone was added to the baseline control wells (the wells that contain medium and cells, but not test compounds) and plate control wells (wells containing medium, but not test compounds and cells). The plates were then placed in an incubator at 37°C to equilibrate temperature and pH.
- 31 - When the cell cultures had reached 100% confluence, the medium was aspirated and each plate was rinsed with 15 ml Hank's Buffered Saline (HBS). The cells were left in the incubator for about 10-15 minutes until the HBS had turned slightly yellow. The HBS was then aspirated and 1 ml trypsin was added to each plate and swirled so as to completely cover the plates. The edges of the plates were gently rapped several times to loosen the cells. After the cells had been dislodged from the surface, 8 ml DMEM containing 10% calf serum and 50 units/ml penicillin and 50 units/ml streptomycin was added to inhibit the trypsin. The plates were rinsed with this medium, and the cells were pipetted into a tube. The cells were centrifuged at 1000 rpm for 5-10 min. in an IEC Centra CL2 centrifuge (produced by Sorvall). Afterwards, the medium was carefully aspirated so as not to dislodge the cells. The cell pellet was suspended in 1600 μl DMEM containing 10% calf serum and 50 units/ml penicillin and 50 units/ml streptomycin, after which 20 ml DMEM supplemented with 2% Cyto-SF3 was added. 50 μl aliquots of this cell suspension was added to the wells of the 96-well microtiter plates prepared above (except for the plate control wells). The plates were then incubated for 4 days at 37°C and 5% C02.
After incubation, the medium was removed by inverting the microtiter plates and shaking them gently, after which they were blotted on absorbent paper. 100 μl chromogenic substrate (3.5 mM o-nitrophenyl-β-D-galactopyranoside, 0.5% Nonidet NP-40, in phosphate buffered saline) was added to each well, and the plates were incubated at 30°C until the optimum absorbance at 405 nm was obtained. The asborbance of the baseline and plate control wells were subtracted from all values.
- 32 - Results Using the general procedure described above, NIH 3T3 cells were co- transfected with DNAs encoding the ml, m3 and m5 receptor subtypes. A compound library containing approximately 35,000 small organic compounds (1 per well) was screened against the receptors by the procedures described above. Fig. 1 illustrates data from one 96-well plate from the screen. On this plate, two compounds were active at one or more of the transfected receptors. In the total screen, four related compounds were identified that showed activity. To determine which of the receptors were activated in the screen, the compounds were tested as described above against each of the receptors transfected into separate cell cultures. Compound A only activated the ml receptor subtype, at which it was a potent partial agonist, inducing a lower maximal response than the reference compound carbachol.
In further experiments, the four compounds were found to selectively activate the ml receptor with no significant activity at the m2, m3, m4 or m5 muscarinic receptors. The most active compound, compound A, was not an antagonist of carbachol-induced responses of the five muscarinic receptor subtypes.
Compound A was further tested for agonist activity against several other receptors at the α-adrenergic receptor subtypes ID, IB, 1A, 2A, 2B and 2C, the histamine HI and the serotonin 5-HT1A and 5-HT2A subtypes. The compound showed no significant activity in these assays. In antagonist experiments, compound A did not inhibit responses of the α-adrenergic receptor subtypes 2 A, 2B or 2C, or the serotonin receptor subtypes 5-HT1A or 5-HT2A. As illustrated in Figure 2, the responses induced by compound A were blocked by the muscarinic antagonist atropine with the same potency as were responses induced by the muscarinic agonist carbachol.
Example XVII - R-SΛ T Assay
R-SAT assays (see U.S. patent no. 5,707,798, incorporated herein by reference) were carried out where cells transfected with ml, m3 or m5 receptors were exposed to seven compounds at 1.5 μM concentration. Cellular response is expressed as a percentage of the maximum response of the cells (defined as response to 10 μM carbachol). The results are presented in the following table.
- 33 - Compound Receptor and Concentration ml m3 m5
1.5 M 1.5 M 1.5 M
A 107 +/- 9 7 +/- 8 j +/- 8 (Example I)
B 76 +/- 11 7 +/- 9 -6 +/- 10
(Example IX)
C 91 +/- 9 4 +/- 9 0 +/- 12
(Example XV)
D 72 +/- 9 13 +/- 7 2 +/- 15
(Example X)
E 42 +/- 13 9 +/- 3 -3 +/- 2 (Example XI)
F 65 +/- 9 9 +/- 7 5 +/- 11 (Example XII)
G1 66 +/- 19 16 +/- 12 7 +/- 11
Figure imgf000036_0001
*4-«-Butyl-l -[4-p] en} Δ-4- ■oxo- 1 -butyl]piperidine
As indicated above, the compounds are selective agonists of the ml receptor.
The invention described and claimed herein is not to be limited in scope by the specific embodiments herein disclosed, since these embodiments are intended as illustrations of several aspects of the invention. Any equivalent embodiments are intended to be within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.
Various references are cited herein, the disclosures of which are incorporated by reference in their entireties.
- 34 -

Claims

We claim:
1. A compound of formula (I):
.X (R2)ΓÇ₧
XT 4 (Xs 5^ „ „C-UH Λ, Y v A
(R.X ( 2 V)?
X. ,N x;
wherein
Xi, X2, X3, X4 and X5 are selected from C, N and O; k is 0 or 1 ; t is 0, 1 or 2;
Ri is straight or branched-chain C╬╣-8 alkyl, C2-8 alkenyl, Cj-8 alkynyl, C|-8 alkylidene, C╬╣-8 alkoxy, C╬╣-8 heteroalkyl, C╬╣- aminoalkyl, C\.% haloalkyl, C╬╣-8 alkoxycarbonyl, C╬╣-8 hydroxyalkoxy, C╬╣-8 hydroxyalkyl, -SH, C╬╣- alkylthio, -0-CH2- C5-6 aryl, -C(0)-C5.6 aryl substituted with C╬╣-3 alkyl or halo; C5-6 aryl or C5- cycloalkyl optionally comprising 1 or more heteroatoms selected from N, S and O; - C(0)NR3R4, -NR3R4, -NR3C(0)NR4R5, -CR3R4, -OC(0)R3, -(O)(CH2)sNR3R4 or - (CH )sNR3R╬╣; where R3, P and R5 are the same or different, each independently being selected from H, C╬╣-6 alkyl; C5- aryl optionally comprising 1 or more heteroatoms selected from N, O and S, and optionally substituted with halo or C╬╣-6 alkyl; C3-6 cycloalkyl; or R3 and > together with the N atom, when present, form a cyclic ring structure comprising 5-6 atoms selected from C, N, S and O; and s is an integer from 0 to 8;
A is C5.12 aryl or C5-7 cycloalkyl, each optionally comprising 1 or more heteroatoms selected from N, S and O; R2 is H, amino, hydroxyl, halo, or straight or branched-chain C╬╣-6 alkyl, C2- alkenyl, C2-6 alkynyl, C╬╣- alkoxy, C╬╣-6 heteroalkyl, C╬╣-6 aminoalkyl, C╬╣-6 haloalkyl, C1.6 alkoxycarbonyl, C[-6 alkylthio, -CN, -CF3, -OR3, -COR3, N02, -NHR3, - NHC(0)R3, -C(0)NR3R4, -NR3R4, -NR3C(0)NR4R5, -OC(0)R3, -C(O)R3R4, -O(CH2)qNR3, -CNR3R4 or -(CH2)qNR3R,; where q is an integer from 1 to 6; n is 0, 1 , 2, 3 or 4, the groups R2, when n > 1 , being the same or different; p is 0 or an integer from 1 to 5;
- 35 - Y is O. S, CHOH, -NHC(O)-, -C(O)NH-, -C(O)-, -OC(O)-, NR7 or -CH=N-, and R7 is H or C╬╣-4. alkyl; or absent;
Z is CR8R wherein R8 and R9 are independently selected from H, and straight or branched-chain C╬╣-8 alkyl; provided where -(CH2)P-Y- is -(CH2)3-C(0)- or -(CH2)3-S-; and X, through X5 are
C; that -A-(R2)n and Ri are not together: o-methyl-phenyl and n-butyl, respectively; phenyl and n-butyl, respectively; or p-fluoro-phenyl and -0-(CH2)2CH3, respectively; or a pharmaceutically acceptable salt, ester or prodrug thereof.
2. The compound of claim 1, wherein:
Xi, X2, X3, t and X5 are C; or one of Xls X2, X3, X4 or X5 is O or N and the others are C; k is 0 or 1; t is l ;
Ri is straight or branched-chain C╬╣-8 alkyl, C2- alkenyl, C2-8 alkynyl, C╬╣-8 alkylidene, C╬╣-8 alkoxy, C╬╣-8 aminoalkyl, C╬╣-8 haloalkyl, C╬╣-8 alkoxycarbonyl, -C(0)NR3R4, -NR3R1, -NR3C(0)NR4R5, -OC(0)R3, or -(CH2)SNR3R4; where R3, t and R5 are the same or different, each independently being selected from H and C╬╣-6 alkyl; and s is an integer from 1 to 8; n is 1, 2 or 3; and A is phenyl or naphthyl; where R2 is straight or branched-chain C╬╣-6 alkyl, C2.6 alkenyl, C2-6 alkynyl, C╬╣-6 alkoxy, C╬╣-6 aminoalkyl, C╬╣-6 haloalkyl, C╬╣-6 alkoxycarbonyl, -CN, -CF3, -OH, -COR3, -NHR3, -NHC(0)R3, -C(0)NR3R4, -NR3R4, -NR3C(0)NR4R5, -OC(0)R3, or -CH2)qNR3R4; where q is an integer from 1 to 6; or
A is aryl comprising 1 or more heteroatoms selected from N, S and O; R2 is H, halo, straight or branched-chain C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C╬╣-6 alkoxy, C╬╣- heteroalkyl, C╬╣-6 aminoalkyl, C╬╣-6 haloalkyl, C╬╣-6 alkoxycarbonyl, -CN, - CF3, OH, -COR3, -NHR3, -NHC(0)R3, -C(0)NR3R4, -NR3R4, -NR3C(0)NR4R5, - OC(0)R3 or -(CH2)qNR3R4; or a pharmaceutically acceptable salt, ester or prodrug thereof.
3. A compound of claim 1 or 2, wherein p is 3.
- 36 -
4. A compound of claim 1 or 2, wherein k is 0.
5. The compound of claim 1 :
(R.X
(R2)n
K N— (CHΛ -Y- II
6. The compound of claim 5 :
R,
(R.X
X N— (CH2)p~Y^ χ Ha
\ / ╬╝ //
7. A compound of claim 6, wherein t is 1 and Y is -C(O)-, -NHC(O)-, S, O or - OC(O)-.
8. The compound of claim 7, wherein X3 is C.
9. The compound of claim 8, wherein Ri is alkyl.
10. The compound of claim 9, wherein R2 is alkyl, aminoalkyl, alkoxy or hydroxyl.
11. A compound of claim 10, wherein p is 3.
12. A compound of claim 11, wherein Ri is C -8 alkyl and R2 is methyl, hydroxyl or alkoxy.
13. A compound of claim 12, wherein Y is -C(O)- or O.
14. The compound of claim 9, wherein R2 is halo.
15. The compound of claim 6, wherein t is 0.
16. The compound of claim 8, wherein Ri is alkoxy.
17. The compound of claim 8, wherein Ri is benzyl or phenyl.
18. The compound of claim 7, wherein X3 is N.
19. The compound of claim 18, wherein Ri is alkyl or alkoxy.
20. The compound of claim 18, wherein Ri is benzyl or phenyl.
21. The compound of claim 19, wherein R2 is alkyl or alkoxy.
22. The compound of claim 20, wherein R2 is alkyl or alkoxy.
23. The compound of claim 7, wherein X3 is O.
24. The compound of claim 23, wherein R\ is alkyl.
25. The compound of claim 24, wherein R2 is alkyl or alkoxy.
- 37 -
26. The compound of claim 24, wherein R2 is halo.
27. The compound of claim 5:
R,
(Ri \)h
NΓÇö (CH2)p-Y- Ilb
28. A compound of claim 27, wherein Y is -C(O)-, -NHC(O)-, S, O or -OC(O)-.
29. The compound of claim 28, wherein X3 is C.
30. The compound of claim 29, wherein Ri is alkyl.
31. The compound of claim 30, wherein R2 is alkyl, aminoalkyl, alkoxy or hydroxyl.
32. A compound of claim 31, wherein p is 3.
33. A compound of claim 32, wherein R\ is C2-8 alkyl and R2 is methyl, hydroxyl or alkoxy.
34. A compound of claim 33, wherein Y is -C(O)- or O.
35. The compound of claim 30, wherein R2 is halo.
36. The compound of claim 27, wherein t is 0.
37. The compound of claim 29, wherein Rj is alkoxy.
38. The compound of claim 29, wherein R\ is benzyl or phenyl.
39. The compound of claim 28, wherein X3 is N.
40. The compound of claim 39, wherein R\ is alkyl or alkoxy.
41. The compound of claim 39, wherein Ri is benzyl or phenyl.
42. The compound of claim 40, wherein R2 is alkyl or alkoxy.
43. The compound of claim 41 , wherein R2 is alkyl or alkoxy.
44. The compound of claim 28, wherein X3 is O.
45. The compound of claim 44, wherein Ri is alkyl.
46. The compound of claim 45, wherein R is alkyl or alkoxy.
47. The compound of claim 45, wherein R2 is halo.
48. A method of agonizing a muscarinic receptor comprising contacting said receptor with an effective amount of a compound of formula (I):
,x. (R2)n
Xi
(R,X (CH2)
*-2 ,N 2)V Y-
Γûá x.'
- 38 - wherein
Xi, X2, X3, Xi and X5 are selected from C, N and O; k is 0 or 1 ; t is 0 or 1 ;
Ri is straight or branched-chain C╬╣-8 alkyl, C2-8 alkenyl, C -8 alkynyl, C╬╣-8 alkylidene, C╬╣-8 alkoxy, C╬╣-8 heteroalkyl, C╬╣-8 aminoalkyl, C╬╣-8 haloalkyl, C╬╣-8 alkoxycarbonyl,
C╬╣-8 hydroxyalkoxy, C╬╣-8 hydroxyalkyl, -SH, C1-8 thioalkyl, -0-CH2-C5-6 aryl, -C(0)-C5-6 aryl substituted with C╬╣-3 alkyl or halo; C5-6 aryl or C5-6 cycloalkyl optionally comprising 1 or more heteroatoms selected from N, S and O (89620); - C(0)NR3R4, -NR3R╬╣, -NR3C(0)NR4R5, -CR3R╬╣, -OC(0)R3, -C(0)(CH2)sNR3R4 or - (CH2)sNR3 t; where R3, R4 and R5 are the same or different, each independently being selected from H, C╬╣- alkyl; C5- aryl optionally comprising 1 or more heteroatoms selected from N, O and S, and optionally substituted with halo or C╬╣-6 alkyl; C3.6 cycloalkyl; or R3 and R4 together with the N atom, when present, form a cyclic ring structure comprising 5-6 atoms selected from C, N, S and O; and s is an integer from 0 to 8;
A is C5-╬╣2 aryl or C5-7 cycloalkyl, each optionally comprising 1 or more heteroatoms selected from N, S and O;
R2 is H, amino, hydroxyl, halo, or straight or branched-chain C╬╣- alkyl, C2- alkenyl, C2- alkynyl, C╬╣-6 alkoxy, C╬╣-6 heteroalkyl, C╬╣- aminoalkyl, C╬╣-6 haloalkyl, C╬╣-6 alkoxycarbonyl, -CN, -CF3, -OR3, -COR3, N02, -NHR3, -NHC(0)R3, -C(0)NR3R4, -NR3R4, -NR3C(0)NR,R5, -OC(0)R3, -C(0)R3R4, -0(CH2)qNR3, -CNR3R┬╗ or -(CH2)qNR3R4; where q is an integer from 1 to 6; n is 0, 1, 2, 3 or 4, the groups R2, when n > 1, being the same or different; p is 0 or an integer from 1 to 5;
Y is O, S, CHOH, -NHC(O)-, -C(0)NH-, -C(O)-, -OC(O)-, NR7 or -CH=N-, and R7 is H or C alkyl; or absent; Z is CR8R9 wherein R8 and R9 are independently selected from H, and straight or branched chain C╬╣-8 alkyl; or or a pharmaceutically acceptable salt, ester or prodrug thereof.
- 39 -
49. A method of claim 48: (R.X
(R2)n
X 3 ^ NΓÇö (CH2)p-Y- II
50. A method of claim 49, wherein t is 1 and Y is -C(O)-, -NHC(O)-, S, O or -OC(O)-.
51. The method of claim 50, wherein X3 is C.
52. The method of claim 51, wherein Ri is alkyl.
53. The method of claim 52, wherein R2 is alkyl, aminoalkyl, alkoxy or hydroxyl.
54. A method of claim 53, wherein p is 3.
55. A method of claim 54, wherein R\ is C2-8 alkyl and R is methyl, hydroxyl or alkoxy.
56. A method of claim 55, wherein Y is -C(O)- or O.
57. The method of claim 52, wherein R2 is halo.
58. The method of claim 49, wherein t is 0.
59. The method of claim 51, wherein R\ is alkoxy.
60. The method of claim 51 , wherein Ri is benzyl or phenyl.
61. The method of claim 52, wherein X3 is N.
62. The method of claim 61, wherein R\ is alkyl or alkoxy.
63. The method of claim 61, wherein Ri is benzyl or phenyl.
64. The method of claim 62, wherein R2 is alkyl or alkoxy.
65. The method of claim 63, wherein R2 is alkyl or alkoxy.
66. The method of claim 50, wherein X3 is O.
67. The method of claim 66, wherein Ri is alkyl.
68. The method of claim 67, wherein R2 is alkyl or alkoxy.
69. The method of claim 67, wherein R2 is halo.
70. A pharmaceutical composition comprising an effective amount of a compound of formula (I):
(R2)n xr -4.
(X5\ A
(R,X (CH2)p Y
X_ ,N 2 X,
Γûá 40 - wherein
Xi, X2, X3, Xi and X5 are selected from C, N and O; k is 0 or 1 ; t is 0 or 1 ;
Ri is straight or branched-chain C╬╣-8 alkyl, C2- alkenyl, C2-8 alkynyl, C╬╣-8 alkylidene, C╬╣- alkoxy, C╬╣-8 heteroalkyl, C╬╣-8 aminoalkyl, C╬╣-8 haloalkyl, C╬╣-8 alkoxycarbonyl,
C╬╣-8 hydroxyalkoxy, C╬╣-8 hydroxyalkyl, -SH, C╬╣-8 thioalkyl, -0-CH2-C5-6 aryl, -C(0)-C5-6 aryl substituted with C╬╣- alkyl or halo; C5-6 aryl or C5-6 cycloalkyl optionally comprising 1 or more heteroatoms selected from N, S and O; -C(0)NR3R4, -NR3R4, -NR3C(0)NR4R5, -CR3R4, -OC(0)R3, -C(0)(CH2)SNR3R4 or -(CH2)SNR3R4; where R3, ┬╗ and R5 are the same or different, each independently being selected from H, C╬╣-6 alkyl; C5-6 aryl optionally comprising 1 or more heteroatoms selected from N, 0 and S, and optionally substituted with halo or C╬╣-6 alkyl; C3-6 cycloalkyl; or R3 and P4 together with the N atom, when present, form a cyclic ring structure comprising 5- 6 atoms selected from C, N, S and O; and s is an integer from 0 to 8;
A is C5-╬╣2 aryl or C5-7 cycloalkyl, each optionally comprising 1 or more heteroatoms selected from N, S and O; R2 is H, amino, hydroxyl, halo, or straight or branched-chain C╬╣-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C╬╣-6 alkoxy, C╬╣- heteroalkyl, C╬╣- aminoalkyl, Cj-6 haloalkyl, C╬╣-6 alkoxycarbonyl, -CN, -CF3, -OR3, -COR , N02, -NHR3, -NHC(0)R3, -C(0)NR3R4, -NR3R1, -NR3C(0)NR4R5, -OC(0)R3, -C(0)R3R., -0(CH2)qNR3, -CNR3R1 or -(CH2)qNR3R4; where q is an integer from 1 to 6; n is 0, 1 , 2, 3 or 4, the groups R2, when n > 1 , being the same or different; p is 0 or an integer from 1 to 5;
Y is O, S, CHOH, -NHC(O)-, -C(0)NH-, -C(O)-, -OC(O)-, NR7 or -CH=N-, and R is H or C╬╣- alkyl; or absent;
Z is CR8R9 wherein R8 and R are independently selected from H, and straight or branched chain C╬╣-8 alkyl; or a pharmaceutically acceptable salt, ester or prodrug thereof; and a pharmaceutically acceptable carrier.
- 41 -
71. A composition of claim 70 compromising:
(R,X (R2)ΓÇ₧
NΓÇö (CH^-Y- II
72. A composition of claim 71, wherein t is 1 and Y is -C(O)-. -NHC(O)-, S, O or - OC(O)-.
73. The composition of claim 72, wherein X3 is C.
74. The composition of claim 73, wherein R[ is alkyl.
75. The composition of claim 74, wherein R2 is alkyl, aminoalkyl, alkoxy or hydroxyl.
76. A composition of claim 75, wherein p is 3.
77. A composition of claim 75, wherein Ri is C2-8 alkyl and R2 is methyl, hydroxyl or alkoxy.
78. A composition of claim 77, wherein Y is -C(O)- or O.
79. The composition of claim 74, wherein R2 is halo.
80. The composition of claim 71, wherein t is 0.
81. The composition of claim 73 , wherein Ri is alkoxy.
82. The composition of claim 73, wherein Ri is benzyl or phenyl.
83. The composition of claim 74, wherein X3 is N.
84. The composition of claim 82, wherein Ri is alkyl or alkoxy.
85. The composition of claim 82, wherein R\ is benzyl or phenyl.
86. The composition of claim 83, wherein R2 is alkyl or alkoxy.
87. The composition of claim 84, wherein R2 is alkyl or alkoxy.
88. The composition of claim 72, wherein X3 is O.
89. The composition of claim 88, wherein R] is alkyl.
90. The composition of claim 89, wherein R2 is alkyl or alkoxy.
91. The composition of claim 87, wherein R2 is halo.
92. A method of treating the symptoms of a disease or condition associated with reduced levels of acetylcholine, said method comprising administering a therapeutically effective amount of one or more compounds of claim 1.
93. The method of claim 92, wherein said disease or condition is neurogenerative disease, cognitive impairment, age-related cognitive decline or dementia.
- 42 -
94. A method of treating the symptoms of a disease or condition associated with increased intraocular pressure, said method comprising administering a therapeutically effective amount of one or more compounds of claim 1.
95. The method of claim 94, wherein said disease is glaucoma.
96. A method of treating the symptoms of a disease or condition associated with reduced levels of acetylcholine, said method comprising administering a therapeutically effective amount of a composition of claim 70.
97. The method of claim 96, wherein said disease or condition is neurogenerative disease, cognitive impairment, age-related cognitive decline or dementia.
98. A method of treating the symptoms of a disease or condition associated with increased intraocular pressure, said method comprising administering a therapeutically effective amount of a composition of claim 70.
99. The method of claim 98, wherein said disease is glaucoma.
- 43 -
PCT/US1999/007057 1998-03-31 1999-03-31 Compounds with activity on muscarinic receptors WO1999050247A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
NZ507204A NZ507204A (en) 1998-03-31 1999-03-31 Substituted piperidine and piperazine derivatives having activity on muscarinic receptors
MXPA00009569A MXPA00009569A (en) 1998-03-31 1999-03-31 Compounds with activity on muscarinic receptors.
AU32187/99A AU762726B2 (en) 1998-03-31 1999-03-31 Compounds with activity on muscarinic receptors
BR9909277-8A BR9909277A (en) 1998-03-31 1999-03-31 Compounds with activity at muscarinic receptors
EP99914306A EP1068185A1 (en) 1998-03-31 1999-03-31 Compounds with activity on muscarinic receptors
JP2000541152A JP2002509918A (en) 1998-03-31 1999-03-31 Compounds with activity on muscarinic receptors
CA002326804A CA2326804C (en) 1998-03-31 1999-03-31 Compounds with activity on muscarinic receptors
NO20004912A NO319835B1 (en) 1998-03-31 2000-09-29 Compounds having an effect on muscarinic receptors, their uses, and pharmaceutical compositions which include them.
US11/933,177 US20080108618A1 (en) 1998-03-31 2007-10-31 Compounds with activity on muscarinic receptors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8013398P 1998-03-31 1998-03-31
US60/080,133 1998-03-31

Publications (1)

Publication Number Publication Date
WO1999050247A1 true WO1999050247A1 (en) 1999-10-07

Family

ID=22155464

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/007057 WO1999050247A1 (en) 1998-03-31 1999-03-31 Compounds with activity on muscarinic receptors

Country Status (14)

Country Link
EP (1) EP1068185A1 (en)
JP (1) JP2002509918A (en)
KR (2) KR20060120715A (en)
CN (1) CN1303376A (en)
AR (1) AR014974A1 (en)
AU (1) AU762726B2 (en)
BR (1) BR9909277A (en)
CA (1) CA2326804C (en)
MX (1) MXPA00009569A (en)
NO (1) NO319835B1 (en)
NZ (2) NZ507204A (en)
RU (2) RU2230740C2 (en)
WO (1) WO1999050247A1 (en)
ZA (1) ZA200005149B (en)

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001005763A2 (en) * 1999-07-16 2001-01-25 Acadia Pharmaceuticals, Inc. Compounds with activity on muscarinic receptors
WO2003057672A2 (en) * 2001-12-28 2003-07-17 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
US6624162B2 (en) 2001-10-22 2003-09-23 Pfizer Inc. Imidazopyridine compounds as 5-HT4 receptor modulators
US6951867B2 (en) 2002-09-20 2005-10-04 Pfizer Inc. N-substituted piperidinyl-imidazopyridine compounds as 5-HT4 receptor modulators
US6979690B2 (en) 2002-01-07 2005-12-27 Pfizer Inc. Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators
US7012080B2 (en) 2002-09-20 2006-03-14 Pfizer Inc. Imidazopyridine compounds as 5-HT4 receptor agonists
WO2008087529A1 (en) 2007-01-16 2008-07-24 Siena Biotech S.P.A. Nicotinic acetylcholine receptor modulators
US7550459B2 (en) 2001-12-28 2009-06-23 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
US7595329B2 (en) 2004-06-15 2009-09-29 Pfizer Inc Benzimidazolone carboxylic acid derivatives
US7659394B2 (en) 2004-04-30 2010-02-09 Pfizer Inc Substituted morpholine compounds for the treatment of central nervous system disorders
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
US7691882B2 (en) 2005-10-31 2010-04-06 Eisai R&D Management Co., Ltd. Heterocycles substituted pyridine derivatives and antifungal agent containing thereof
US7737142B2 (en) 2003-08-04 2010-06-15 Richter Gedeon Vegyeszeti Gyar Rt. (Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
US7829585B2 (en) 2005-03-30 2010-11-09 Eisai R&D Management Co., Ltd. Antifungal agent containing pyridine derivative
EP2258357A2 (en) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
US7932272B2 (en) 2003-09-30 2011-04-26 Eisai R&D Management Co., Ltd. Antifungal agent containing heterocyclic compound
WO2011139951A1 (en) 2010-05-03 2011-11-10 Janssen Pharmaceutica Nv Modulators of fatty acid amide hydrolase
US8097610B2 (en) 2005-08-26 2012-01-17 Shionogi & Co., Ltd. Derivative having PPAR agonistic activity
US8110573B2 (en) 2004-12-30 2012-02-07 Astex Therapeutics Limited Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases
US8399442B2 (en) 2005-12-30 2013-03-19 Astex Therapeutics Limited Pharmaceutical compounds
US8435970B2 (en) 2006-06-29 2013-05-07 Astex Therapeutics Limited Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
US8569496B2 (en) 2008-12-17 2013-10-29 Richter Gedeon Nyrt. Piperazine salt and a process for the preparation thereof
US8569497B2 (en) 2008-12-18 2013-10-29 Richter Gedeon Nyrt. Process for the preparation of piperazine derivatives
US8569498B2 (en) 2008-12-18 2013-10-29 Richter Gedeon Nyrt. Process for the preparation of piperazine compounds and hydrochloride salts thereof
US8765765B2 (en) 2007-05-18 2014-07-01 Richter Gedeon Nyrt. Metabolites of (thio) carbamoyl-cyclohexane derivatives
US8802672B2 (en) 2007-12-03 2014-08-12 Richter Gedeon Nyrt. Pyrimidinyl-piperazines useful as D3/D2 receptor ligands
US8829028B2 (en) 2002-05-16 2014-09-09 Serodus As 5-HT4 receptor antagonists for the treatment of heart failure
US8912197B2 (en) 2012-08-20 2014-12-16 Forest Laboratories Holdings Ltd. Crystalline form of carbamoyl-cyclohexane derivatives
US9018214B2 (en) 2011-04-21 2015-04-28 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US9169224B2 (en) 2004-12-30 2015-10-27 Janssen Pharmaceutica Nv Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase
US9617283B2 (en) 2012-10-19 2017-04-11 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US9617248B2 (en) 2012-10-19 2017-04-11 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US9663512B2 (en) 2012-10-19 2017-05-30 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US9783538B2 (en) 2013-12-20 2017-10-10 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US10450269B1 (en) 2013-11-18 2019-10-22 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10556013B2 (en) 2017-06-20 2020-02-11 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism
US11053195B2 (en) 2013-03-15 2021-07-06 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
USRE49110E1 (en) 2008-07-16 2022-06-21 Richter Gedeon Nyrt. Pharmaceutical formulations containing dopamine receptor ligands
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007501254A (en) * 2003-08-05 2007-01-25 サマリタン，ファーマスーティカルス，インク． Sigma-1 receptor ligand with acetylcholinesterase inhibitory properties
CN102558026A (en) * 2011-12-27 2012-07-11 盛世泰科生物医药技术(苏州)有限公司 Synthesis and optimized process of 4-N-butyl-1-[4-(2-methylphenyl)-4-one-1-butyl]piperidine. N-benzyl-4-piperidone (1)
CN102997438A (en) * 2012-10-16 2013-03-27 李誊 Control method of electric water heater for improving heat utilization ratio

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE610830A (en) * 1960-12-01
US2695295A (en) * 1952-12-19 1954-11-23 Mcneilab Inc Unsymmetrical n, n'-substituted ethylenediamine and piperazine compounds
GB874206A (en) * 1956-09-05 1961-08-02 Knoll Ag Basic derivatives of salicylamide
FR1382425A (en) * 1963-01-14 1964-12-18 Ciba Geigy Process for preparing diaza-cyclo-alkanes, inter alia 3-methyl-4-phenyl-1- (2-phenylmercapto-ethyl) -piperazine
FR1543944A (en) * 1967-03-10 1968-10-31 Bruneau & Cie Lab Salicylic acid amide derivatives and their preparation
FR1570446A (en) * 1966-10-11 1969-06-13
DE2259004A1 (en) * 1971-12-03 1973-06-20 Sumitomo Chemical Co ALKYLAMINE DERIVATIVES, THE PROCESS FOR THEIR MANUFACTURING AND MEDICINAL PREPARATIONS CONTAINING THESE COMPOUNDS
FR2261008A1 (en) * 1974-02-18 1975-09-12 Wyeth John & Brother Ltd
US4045566A (en) * 1975-04-15 1977-08-30 John Wyeth & Brother Limited Piperidyl-glycylamide derivatives
WO1996026196A2 (en) * 1995-02-23 1996-08-29 Schering Corporation Benzylpiperidines and piperazines as muscarinic antagonists
WO1998005292A2 (en) * 1996-08-08 1998-02-12 Schering Corporation Piperidine and piperazine derivatives and their use as muscarinic antagonists
WO1998006697A1 (en) * 1996-08-15 1998-02-19 Schering Corporation Ether muscarinic antagonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1053301A (en) * 1963-01-14
DE2335432A1 (en) * 1973-07-12 1975-01-30 Boehringer Mannheim Gmbh 3,4-DIHYDRO-2H-NAPHTHALINONE- (1) 5-OXY-PROPYL-PIPERAZINE DERIVATIVES AND THE METHOD FOR THEIR PRODUCTION

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2695295A (en) * 1952-12-19 1954-11-23 Mcneilab Inc Unsymmetrical n, n'-substituted ethylenediamine and piperazine compounds
GB874206A (en) * 1956-09-05 1961-08-02 Knoll Ag Basic derivatives of salicylamide
BE610830A (en) * 1960-12-01
FR1382425A (en) * 1963-01-14 1964-12-18 Ciba Geigy Process for preparing diaza-cyclo-alkanes, inter alia 3-methyl-4-phenyl-1- (2-phenylmercapto-ethyl) -piperazine
FR1570446A (en) * 1966-10-11 1969-06-13
FR1543944A (en) * 1967-03-10 1968-10-31 Bruneau & Cie Lab Salicylic acid amide derivatives and their preparation
DE2259004A1 (en) * 1971-12-03 1973-06-20 Sumitomo Chemical Co ALKYLAMINE DERIVATIVES, THE PROCESS FOR THEIR MANUFACTURING AND MEDICINAL PREPARATIONS CONTAINING THESE COMPOUNDS
FR2261008A1 (en) * 1974-02-18 1975-09-12 Wyeth John & Brother Ltd
US4045566A (en) * 1975-04-15 1977-08-30 John Wyeth & Brother Limited Piperidyl-glycylamide derivatives
WO1996026196A2 (en) * 1995-02-23 1996-08-29 Schering Corporation Benzylpiperidines and piperazines as muscarinic antagonists
WO1998005292A2 (en) * 1996-08-08 1998-02-12 Schering Corporation Piperidine and piperazine derivatives and their use as muscarinic antagonists
WO1998006697A1 (en) * 1996-08-15 1998-02-19 Schering Corporation Ether muscarinic antagonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRITTON S B ET AL: "THE USE OF 2-PIPECOLINE IN THE MANNICH REACTION", JOURNAL OF THE AMERICAN PHARMACEUTICAL ASSOCIATION SCIENTIFIC EDITION, vol. 43, no. 11, 1 November 1954 (1954-11-01), pages 641 - 643, XP002071842 *
KAISER C ET AL: "SYNTHESIS AND ANTIMUSCARINIC ACTIVITY OF SOME 1-CYCLOALKYL-1 -HYDROXY-1-PHENYL-3-(4-SUBSTITUTED PIPERAZINYL)-2- PROPANONES AND RELATED COMPOUNDS", JOURNAL OF MEDICINAL CHEMISTRY, vol. 36, no. 5, 5 March 1993 (1993-03-05), pages 610 - 616, XP002071849 *

Cited By (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
US7485651B2 (en) 1998-03-31 2009-02-03 Acadia Pharmaceuticals, Inc. Compounds with activity on muscarinic receptors
WO2001005763A2 (en) * 1999-07-16 2001-01-25 Acadia Pharmaceuticals, Inc. Compounds with activity on muscarinic receptors
WO2001005763A3 (en) * 1999-07-16 2002-01-17 Acadia Pharm Inc Compounds with activity on muscarinic receptors
US6624162B2 (en) 2001-10-22 2003-09-23 Pfizer Inc. Imidazopyridine compounds as 5-HT4 receptor modulators
WO2003057672A2 (en) * 2001-12-28 2003-07-17 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
WO2003057672A3 (en) * 2001-12-28 2003-11-13 Acadia Pharm Inc Tetrahydroquinoline analogues as muscarinic agonists
US8680115B2 (en) 2001-12-28 2014-03-25 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
US7307075B2 (en) 2001-12-28 2007-12-11 Acadia Pharmaceuticals Inc. Tetrahydroquinoline analogues as muscarinic agonists
US9522906B2 (en) 2001-12-28 2016-12-20 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
US7550459B2 (en) 2001-12-28 2009-06-23 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
US7576100B2 (en) 2001-12-28 2009-08-18 Acadia Pharmaceuticals, Inc. Muscarinic agonists
US7576078B2 (en) 2001-12-28 2009-08-18 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
US6979690B2 (en) 2002-01-07 2005-12-27 Pfizer Inc. Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators
US8829028B2 (en) 2002-05-16 2014-09-09 Serodus As 5-HT4 receptor antagonists for the treatment of heart failure
US6951867B2 (en) 2002-09-20 2005-10-04 Pfizer Inc. N-substituted piperidinyl-imidazopyridine compounds as 5-HT4 receptor modulators
US7012080B2 (en) 2002-09-20 2006-03-14 Pfizer Inc. Imidazopyridine compounds as 5-HT4 receptor agonists
US7737142B2 (en) 2003-08-04 2010-06-15 Richter Gedeon Vegyeszeti Gyar Rt. (Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists
US7932272B2 (en) 2003-09-30 2011-04-26 Eisai R&D Management Co., Ltd. Antifungal agent containing heterocyclic compound
US7659394B2 (en) 2004-04-30 2010-02-09 Pfizer Inc Substituted morpholine compounds for the treatment of central nervous system disorders
US7595329B2 (en) 2004-06-15 2009-09-29 Pfizer Inc Benzimidazolone carboxylic acid derivatives
US7705020B2 (en) 2004-06-15 2010-04-27 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
US8778936B2 (en) 2004-12-30 2014-07-15 Astex Therapeutics Limited Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases
US9169224B2 (en) 2004-12-30 2015-10-27 Janssen Pharmaceutica Nv Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase
US8110573B2 (en) 2004-12-30 2012-02-07 Astex Therapeutics Limited Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases
US7829585B2 (en) 2005-03-30 2010-11-09 Eisai R&D Management Co., Ltd. Antifungal agent containing pyridine derivative
EP2258357A2 (en) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2258359A2 (en) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
US8097610B2 (en) 2005-08-26 2012-01-17 Shionogi & Co., Ltd. Derivative having PPAR agonistic activity
EP2258358A2 (en) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP2275095A2 (en) 2005-08-26 2011-01-19 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2275096A2 (en) 2005-08-26 2011-01-19 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
US8841327B2 (en) 2005-10-31 2014-09-23 Eisai R&D Management Co., Ltd. Heterocycles substituted pyridine derivatives and antifungal agent containing thereof
US7691882B2 (en) 2005-10-31 2010-04-06 Eisai R&D Management Co., Ltd. Heterocycles substituted pyridine derivatives and antifungal agent containing thereof
US8399442B2 (en) 2005-12-30 2013-03-19 Astex Therapeutics Limited Pharmaceutical compounds
US8435970B2 (en) 2006-06-29 2013-05-07 Astex Therapeutics Limited Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea
WO2008087529A1 (en) 2007-01-16 2008-07-24 Siena Biotech S.P.A. Nicotinic acetylcholine receptor modulators
US8163729B2 (en) 2007-01-16 2012-04-24 Wyeth Modulators of α7 nicotinic acetylcholine receptors and therapeutic uses thereof
US8765765B2 (en) 2007-05-18 2014-07-01 Richter Gedeon Nyrt. Metabolites of (thio) carbamoyl-cyclohexane derivatives
US8802672B2 (en) 2007-12-03 2014-08-12 Richter Gedeon Nyrt. Pyrimidinyl-piperazines useful as D3/D2 receptor ligands
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
USRE49110E1 (en) 2008-07-16 2022-06-21 Richter Gedeon Nyrt. Pharmaceutical formulations containing dopamine receptor ligands
USRE49302E1 (en) 2008-07-16 2022-11-15 Richter Gedeon Nyrt. Pharmaceutical formulations containing dopamine receptor ligands
US8569496B2 (en) 2008-12-17 2013-10-29 Richter Gedeon Nyrt. Piperazine salt and a process for the preparation thereof
US8569497B2 (en) 2008-12-18 2013-10-29 Richter Gedeon Nyrt. Process for the preparation of piperazine derivatives
US8569498B2 (en) 2008-12-18 2013-10-29 Richter Gedeon Nyrt. Process for the preparation of piperazine compounds and hydrochloride salts thereof
WO2011139951A1 (en) 2010-05-03 2011-11-10 Janssen Pharmaceutica Nv Modulators of fatty acid amide hydrolase
US8940745B2 (en) 2010-05-03 2015-01-27 Janssen Pharmaceutica Nv Modulators of fatty acid amide hydrolase
US9688664B2 (en) 2010-05-03 2017-06-27 Janssen Pharmaceutica Nv Modulators of fatty acid amide hydrolase
US9018214B2 (en) 2011-04-21 2015-04-28 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US11866428B2 (en) 2011-04-21 2024-01-09 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US9676768B2 (en) 2011-04-21 2017-06-13 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US8912197B2 (en) 2012-08-20 2014-12-16 Forest Laboratories Holdings Ltd. Crystalline form of carbamoyl-cyclohexane derivatives
US9617283B2 (en) 2012-10-19 2017-04-11 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US9663512B2 (en) 2012-10-19 2017-05-30 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US9617248B2 (en) 2012-10-19 2017-04-11 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US11053195B2 (en) 2013-03-15 2021-07-06 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10450269B1 (en) 2013-11-18 2019-10-22 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9783538B2 (en) 2013-12-20 2017-10-10 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US11643410B2 (en) 2013-12-20 2023-05-09 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US11225476B2 (en) 2013-12-20 2022-01-18 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US10618895B2 (en) 2013-12-20 2020-04-14 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
US10953102B2 (en) 2017-06-20 2021-03-23 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism
US11376330B2 (en) 2017-06-20 2022-07-05 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism
US10918728B2 (en) 2017-06-20 2021-02-16 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism
US11844840B2 (en) 2017-06-20 2023-12-19 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism
US10556013B2 (en) 2017-06-20 2020-02-11 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11746090B2 (en) 2020-06-30 2023-09-05 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4- trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine

Also Published As

Publication number Publication date
RU2230740C2 (en) 2004-06-20
RU2004107218A (en) 2005-08-20
AU762726B2 (en) 2003-07-03
NZ525108A (en) 2005-02-25
BR9909277A (en) 2001-10-16
KR100672186B1 (en) 2007-01-19
CN1303376A (en) 2001-07-11
EP1068185A1 (en) 2001-01-17
JP2002509918A (en) 2002-04-02
CA2326804A1 (en) 1999-10-07
MXPA00009569A (en) 2002-08-06
NO319835B1 (en) 2005-09-19
NO20004912L (en) 2000-11-23
NO20004912D0 (en) 2000-09-29
CA2326804C (en) 2006-05-02
KR20060120715A (en) 2006-11-27
AU3218799A (en) 1999-10-18
RU2278111C2 (en) 2006-06-20
KR20010042248A (en) 2001-05-25
AR014974A1 (en) 2001-04-11
NZ507204A (en) 2003-12-19
ZA200005149B (en) 2002-01-08

Similar Documents

Publication Publication Date Title
AU762726B2 (en) Compounds with activity on muscarinic receptors
US6528529B1 (en) Compounds with activity on muscarinic receptors
JP4792186B2 (en) Sulfonyl carboxamide derivatives, processes for their preparation and their use as medicaments
DE60225162T2 (en) PHENYLPIPERAZINE DERIVATIVES AS SEROTONIN RECOVERY INHIBITORS
JP2941945B2 (en) Novel 4-arylpiperazines and 4-arylpiperidines
JPH03181461A (en) Antiarrhythmic agent
US20040072822A1 (en) N,N-disubstituted diazocycloalkanes
JP2007297410A (en) Muscarinic antagonist
EP0937715A1 (en) Tetrahydrobenzindole compounds
EP0682015A1 (en) Piperidine derivates and anti-platelet agents containing the same
US5958942A (en) Tricyclic nitrogen ring compounds, their production and use
NZ243337A (en) 1-piperidyl substituted quinoline derivatives and pharmaceutical compositions
CA2543133A1 (en) Compounds with activity on muscarinic receptors
DE19746612A1 (en) New 2-substituted 1,2-benzisothiazole derivatives
US6271234B1 (en) 1,4-disubstituted piperazines
JPH037280A (en) Novel benzothiopyranylamine
US20060148821A1 (en) N,N-disubstituted diazocycloalkanes
US20090124630A1 (en) 3, 4-dihydro-2-naphthamide derivatives as selective dopamine d3 ligands
DE60213043T2 (en) Process for the preparation of 2- (4-alkyl-1-piperazinyl) -benzaldehyde and -benzylidenyl derivatives by nucleophilic substitution of 2-fluorobenzaldehyde with 4-alkyl-1-piperazines in water as solvent
US5929078A (en) 1- 2-(2,3-Dihydro-1H-inden-1-yl)ethyl!-4-(naphthalen-1-yl) piperazine, derivatives, preparation thereof and therapeutical use thereof
EP0578419B1 (en) Pyridine derivatives and pharmaceutical compositions containing them
NZ270500A (en) 1-indenylethyl-4-naphthyl piperazines and pharmaceutical compositions thereof
CA2259218C (en) Tetrahydrobenzindole compound
FR2717174A1 (en) Use of 4-amino-5-chloro-2-methoxy-benzoic acid piperidino-ethyl ester(s)
JPH0673010A (en) Pyridine derivative

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99806618.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000/05149

Country of ref document: ZA

Ref document number: 32187/99

Country of ref document: AU

Ref document number: 200005149

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2326804

Country of ref document: CA

Ref document number: 2326804

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 507204

Country of ref document: NZ

Ref document number: 1020007010780

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/009569

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2000 541152

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1999914306

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2000/423/KOL

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 1999914306

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020007010780

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 32187/99

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1020007010780

Country of ref document: KR